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ABSTRACT 
 
 Bacterial infections are becoming progressively more difficult to treat due to 
antibiotic resistance and the decreasing rate at which new antibiotics are brought to 
market. The Turos laboratory has attempted to tackle this problem for the last 15 years 
with the discovery of N-thiolated β-lactams leading to the design of polyacrylate 
nanoparticles to deliver these and other drugs. Chapter 1 discusses many reported 
instances of utilizing different types of polymeric nanoparticles to deliver antibiotics. 
Poly(lactic-co-glycolic acid) (PLGA), poly(alkyl cyanoacrylate) (PACA), poly(styrene-
co-butylacrylate), and chitosan are the main polymers used to make nanoparticles. 
Chapter 2 describes the synthesis, antibacterial activity, and mechanism of action of N-
acyl ciprofloxacins, which have demonstrated in vitro bioactivity against Staphyloccocus 
aureus, methicillin-resistant Staphylococcus aureus¸ Bacillus anthracis, Enterococcus 
faecalis, Bartonella, and E. coli. Antimicrobial activity was found to diminish with 
increasingly lipophilic acyl groups of the derivatives. The N-acyl ciprofloxacins were 
found to utilize the same mechanism of action as the parent drug, ciprofloxacin, however, 
several exhibited lower mutation frequencies. Chapter 3 discusses the use of the N-acyl 
ciprofloxacins as probes for experimentation on the poly(vinyl benzoate) nanoparticles. 
These compounds were incorporated into poly(vinyl benzoate) nanoparticles, also 
designed in the Turos laboratory, to determine the effects of the lipophilic acyl groups on 
xxii 
 
drug loading and drug release. N-acyl ciprofloxacins with higher lipophilicities (predicted 
logP values) experienced higher drug loading than the less lipophilic counterparts. 
However, the nanoparticles were unable to release large amounts of entrapped drug. N-
acyl ciprofloxacins with increased hydrophilicity were found to either not be incorporated 
at all, or in incredibly small amounts. Drug release studies of these drugs indicate that 
possibly the hydrophobic compounds that were associated with the nanoparticles were 
done so via adsorption onto the surface resulting in a burst release of drug. The work is 
concluded in Chapter 4, followed by experimental procedures and spectral data in 
Chapters 5 and Appendix 1.  
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CHAPTER ONE 
 
THE USE OF POLYMER NANOPARTICLES AS ANTIBIOTIC DELIVERY 
SYSTEMS OR AS ANTIBACTERIAL MATERIALS 
 
 
1.1 Introduction 
As antibiotic resistance continues to plague mankind, researchers have been charged with 
designing novel antibacterial compounds with ever increasing potency. Parallel to this 
approach, the delivery of both old and new drugs have been extensively studied, 
including the use of small particles as carriers for these compounds. Nanoparticle drug 
delivery has the opportunity to protect drugs throughout their journey in the body, bypass 
some resistance mechanisms, and has the potential to selectively deliver drugs to a 
desired target as a means for minimizing side effects.  
 
1.1.1 Preparation of Nanoparticles 
Several reviews have been published on the preparation and characteristics of 
nanoparticles.1 While there are many ways to create these particles, several will be 
discussed in this chapter and are herein described. 
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1.1.1.1 Emulsion Evaporation Technique 
The emulsion evaporation method involves the dissolving of the desired polymer in an 
organic solvent which is then added to an aqueous solution containing the surfactant. The 
use of intense stirring, ultrasonication, or being subjected to increased pressure causes the 
nanoparticles to form after which the solvent is evaporated yielding the desired 
nanoparticles. This technique is widely used due to the flexability it provides with respect 
to the type of drug being incorporated. Two types of emulsions can be involved in this 
technique, oil in water emulsions and water in oil in water emulsions, shown in Figure 
1.1.  
 
 
Figure (1.1) Visual representations of oil in water (o/w) and water in oil in water (w/o/w) 
emulsions 
 
As can be deduced from Figure 1.1, the different emulsions provide different 
environments for drug loading. The oil in water emulsion is the preferred method for the 
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encapsulation of lipophilic drugs, as they would be inclined to stay within the 
hydrophobic medium during the nanoparticle preparation. The water in oil in water 
emulsion allows the incorporation of hydrophilic drugs as those molecules would prefer 
to maintain their position within the water capsules within the oil system.  
 
1.1.1.2 Nanoprecipitation 
Relatively akin to the emulsion evaporation technique, nanoprecipitation involves the 
similar procedural setup, where the desired polymer and drug are dissolved in a miscible 
organic solvent, which is then added (usually in a controlled manner such as a syringe 
pump or addition funnel) to the aqueous solution of surfactant upon which nanoparticles 
begin to from immediately and create a suspension. After the organic solvent has been 
removed (usually via evaporation) the nanoparticle suspension is available for further 
experimentation.  
 
1.1.1.3 Emulsion Polymerization 
In emulsion polymerization, the polymeric core of the nanoparticle is formed in situ 
during the nanoparticle process. The monomers that comprise the polymeric core are 
dissolved/mixed with an aqueous solution of surfactant and the ingredients used to 
initiate the polymerization process. As “micelles” form around the hydrophobic 
monomers, polymerization takes place finalizing the process. An example is shown in 
Figure 1.2. 
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Figure (1.2) Visual representation of emulsion polymerization process 
 
1.1.1.4 Ionotropic Gelation 
Usually used for the formation of chitosan nanoparticles, in this technique involves 
exploiting the amine functionality of chitosan and it’s interaction with tripolyphosphate, 
Figure 1.3.2 
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Figure (1.3) Ionic crosslinking with TPP and coacervation to prepare nanoparticles 
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1.1.2 Types of Drug Loading 
Drugs/molecules can either be trapped within the nanoparticle’s protective shell or 
adsorbed onto the surface, Figure (1.4). 
 
 
Figure (1.4) Adsorption onto the surface (left) and molecules loaded inside of the 
nanoparticle 
 
Molecules loaded inside of the nanoparticle can be done in multiple ways as well, with 
the two more prevalent being encapsulation versus the covalent binding of the molecule 
to polymeric core, Figure 1.5.  
 
 
Figure (1.5) Covalently bound drug (left) versus encapsulated drug (right) 
6 
 
 
Molecules adsorbed to the surface of the molecule tend to be released at an increased rate 
than those that are trapped within, this is usually referred to as a burst release, Figure 1.6.  
 
Figure (1.6) Graphical representation of burst release. After a relatively short period of 
incubation, drug molecules adsorbed to the surface of the nanoparticle are released. 
 
Molecules that are encapsulated are usually released through slow leakage, of which the 
rate is increased upon enzymatic degradation of the polymeric core, while those 
molecules that are covalently bound to the polymeric core are usually done so via ester 
and amide bonds such as that enzymatic hydrolysis is able to release the free drug as well 
as break up the polymer to allow drug release. 
 
While a wide variety of nano-sized particles exist in the literature, this chapter focuses on 
the use of polymeric nanoparticles as either antibiotic carrying vehicles, or as 
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antibacterial systems themselves. Four types of organopolymer based nanoparticle 
systems will be discussed including those particles comprised of poly(lactic-co-glycolic 
acid), chitosan, poly(alkyl cyanoacrylate), and polyacrylates. 
 
1.2 Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles 
In 1994 Robert Langer’s laboratory published their synthesis of poly(lactic-co-glycolic 
acid) nanoparticles using the oil in water technique.3 Driven by the idea of incorporating 
a drug into a nanosphere made of biodegradable components to create a long term 
delivery device, they covalently bound polyethylene glycol (PEG) to the PLGA polymer 
core. Utilizing the hydrophobic nature of PLGA and the hydrophilic nature of PEG, 
(Figure 1.7) the researchers were able to create stable emulsions and upon lyophilization 
obtained resuspendable nanoparticles with no aggregation. Through the use of quasi 
electric light scattering and atomic force microscopy the nanoparticles were shown to 
have a mean diameter of 140 nm. 
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Figure (1.7) PLGA (left) and PEG (right) 
 
Lidocaine (Figure 1.8) was used as the model drug for release studies and it was reported 
to have an encapsulation efficiency of greater than 95%. Various concentrations of 
lidocaine in the nanoparticles were tested for drug release and it was found that the 
nanoparticles with higher drug loading gave slower release times, up to 14 hours for 
8 
 
100% release. The authors hypothesized that this was due to a possible crystallization of 
the drug within the nanoparticle, determined via calorimetric and X-ray diffraction 
studies.  
O
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Figure (1.8) Lidocaine 
 
Since this study, an incredible amount of research has been done on PLGA nanoparticles 
using various synthetic procedures, surfactants, and drugs for delivery. The following 
examples pertain only to those involved with antibiotic delivery.  
 
1.2.1 Aminoglycosides/Glycopeptides 
 
1.2.1.1 Gentamicin Loaded PLGA Nanoparticles 
Gentamicin (Figure 1.9) was incorporated into PLGA nanoparticles by Lecaroz et al. in 
2007, in order to determine the activity in vivo against Brucella melitensis.4 The authors 
stated that the highly polar structure of gentamicin creates difficulty for the drug to obtain 
intracellular activity, requiring the need for a drug delivery system that could alleviate 
this problem.  
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Figure (1.9) Gentamicin 
 
Using the water oil solvent evaporation protocol, the gentamicin loaded nanoparticles 
were found to have an average mean diameter of 310 nm, with a drug loading of 6.2 µg 
drug/mg nanoparticles. In vivo biodistribution studies were done by injecting mice with 
nanoparticles containing fluorescent probes. It was found that the nanoparticles, after 
liver and spleen uptake (desired target organs), were completely degraded in under one 
week. Due to the larger gentamicin loading and ability to activate monocytes of the 
microspheres, the nanoparticle portion of this study was abandoned.  
 
In 2011, Imbuluzqueta et al. published their work involving the use of gentamicin loaded 
PLGA nanoparticles and the in vitro activity of these particles against B. melitensis.5 The 
authors used two different types of particles to attempt delivery. The first design involved 
the use of hydrophobic ion pairing gentamicin with a surfactant, bis(2-ethylhexyl) 
sulfosuccinate sodium salt (Aerosol OT™, AOT) (Figure 1.10). This ion pairing gave the 
overall molecule a lipophilic and hydrophilic character allowing for it to particulate under 
its own accord. 
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Figure (1.10) Bis(2-ethylhexyl) sulfosuccinate sodium salt 
 
The second approach involved the more common PLGA nanoparticle synthesis using the 
oil in water solvent evaporation technique. The ion paired gentamicin was used in this 
formulation as well. These nanoparticles were found to have an average size between 250 
and 330 nm. High encapsulation efficiencies were obtained, from 98 to 100 percent. Drug 
release from the PLGA nanoparticles was determined as well. A small burst release 
(Figure (1.6) was observed, under 20% for most cases. The authors attributed this to the 
increased hydrophobicity of the gentamicin-AOT pairing which would account for an 
increased interaction between the drug and the lipophilic interior of the particles. Overall 
drug release was slow, with 100% release being achieved for one of the formulations 
after 70 days. The polymeric nanoparticles and the gentamicin-AOT ion pairing were 
tested in vitro against B. melitensis and it was found that neither of these greatly affected 
the activity of the drug. However, this study did show the ability to tune an antibiotic to 
obtain better suitability for nanoparticle encapsulation while maintaining the original 
drug’s activity, which could lead to important nanoparticle research down the line. 
 
1.2.1.2 Streptomycin and Vancomycin Loaded PLGA Nanoparticles 
In 2009, Schwarz et al. produced a patent involving the use of PLGA nanoparticles to 
deliver several antibiotics, including streptomycin and vancomycin (Figure 1.11).6 
11 
 
 
H
N
N
H
H
N
N
H
NH
OHO
O
O NH2
O
O
O
OO
Cl
HO
HO
OH
O
O
OH
H2N
O
Cl
OH
O
H
N
NH
O
CO2H
OH
HO OH
O
O
HN
HO
HO
HO
OHO
OHC
O
HO
N
N
OH
OH
H2N
NH2
NH2
NH2
 
Figure (1.11) Streptomycin (left) and Vancomycin (right)  
 
The authors used the emulsification solvent evaporation technique to create a variety of 
PLGA nanoparticles with an array of surfactants. Streptomycin loaded particles were 
obtained with sizes between 72 and 241 nm and the vancomycin loaded nanoparticles 
were shown to have diameters between 71 and 182 nm. 
 
In vivo testing of the streptomycin nanoparticles was done on mice infected with 
Mycobacterium tuberculosis, shown in Table 1.1. 
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Table (1.1) In vivo assays determining efficacy of streptomycin loaded nanoparticles 
against M. tuberculosis 
Treatment Number of 
Deaths 
Survival Rate at 
14 days (%) 
Survival Rate at 
28 days (%) 
Survival Rate 
at 56 days 
(%) 
Untreated 12.12 0 0 0 
Free Drug 
(Positive) 
1/12 92 92 92 
Free Drug 
(Comparative) 
5/12 83 58 58 
Nanoparticle 
Formulation 1 
2/12 83 75 75 
Nanoparticle 
Formulation 2 
0/12 100 100 100 
 
 
As can be seen from the in vivo data, the drug loaded nanoparticles were more effective 
than free drug at treating the infected mice. Pulmonary bacterial count experiments also 
showed the particles exhibiting significant improvement over untreated mice and those 
treated with free streptomycin.  
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The data from the in vivo testing of the vancomycin nanoparticles on mice infected with 
Staphylococcus pneumonia is shown in Table 1.2. Again, the nanoparticles were effective 
at increasing the activity of the drug in the infected mice. 
 
Table (1.2) In vivo assays determining efficacy of vancomycin loaded nanoparticles 
(NP1, NP2, NP3) against S. pneumonia. 
     Deaths 
Treatment 1d 2d 3d 4d 5d 6d 7d 8d 9d 10d % Survived 
Free Drug 0 0 0 1 3 2 0 1 0 0 30 
NP 1 0 0 0 0 0 0 0 0 0 0 100 
NP 2 0 0 0 0 0 0 0 0 0 0 100 
NP 3 0 0 0 0 1 0 0 0 0 0 90 
 
 
1.2.1.3 Teicoplanin Loaded PLGA Nanoparticles 
The treatment of osteomyelitis currently involves the use of poly(methyl methacrylate) 
(PMMA) bone cement implants, which often require a secondary surgery for removal. In 
2010, Peng et al. published their efforts on the use of teicoplanin loaded mPEG 
(methoxypoly(ethylene glycol))-PLGA nanocomposites as a biodegradable hydrogel 
alternative (Figure 1.12).7 The authors synthesized the diblock copolymer using stannous 
2-ethylhexanoate, shown in Figure 1.13. 
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Figure (1.12) Teicoplanin 
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Figure (1.13) Synthesis of mPEG-PLGA diblock copolymer 
 
Several different formulations were used in the synthesis of the copolymer, creating 3 
different hydrogels, based on the amount of mPEG used. It was found that as the amount 
of mPEG decreased, the particle size increased, which was attributed to larger 
hydrophobic chain lengths. The hydrogels were found to be soluble in water, allowing 
them to be injectable, and it was shown that they were biodegradable with up to 70 
percent of the polymer being degraded within 31 days. Drug release studies revealed no 
burst release to speak of, and after 31 days 60 to 73 percent of the teicoplanin had been 
15 
 
released. Both the PMMA cement beads and the mPEG-PLGA hydrogels were able to 
treat osteomyelitis in rabbits in vivo. The ability of these biodegradable hydrogels to 
demonstrate a sustained release of teicoplanin and the lack of disadvantages, such as 
future surgical removal provides ample evidence towards the use of nanomaterials in the 
treatment of osteomyelitis. 
 
1.2.2 β-Lactams 
 
1.2.2.1 Nafcillin Loaded PLGA Nanoparticles 
The use of nafcillin loaded PLGA nanoparticles was reported in 2008 by Pillai et al and 
was shown to be effective against Staphylococcus aureus infected osteoblasts (Figure 
1.14).8  
 
N S
O
HO
O
NHO
O
H
 
Figure (1.14) Nafcillin 
 
The nanoparticles were created via emulsion solvent evaporation with PVA as the 
surfactant. Using multiple formulations for the synthesis of the particles, the authors 
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reported that the size of the particles decreased dramatically when nafcillin was 
introduced (Figure 1.15). 
 
 
Figure (1.15) Nanoparticle size distributions 
 
 The authors hypothesize that this is due to the decreased interfacial tension between the 
two phases leading to increased area to volume ratio caused by the lipophilic nafcillin. 
Drug loading for each nanoparticle was determined to be from 7 and 12 percent. In vitro 
release studies were performed and it was found that the nanoparticles released 42 to 47 
percent of the drug within the first 2 days, and 100 percent of the drug after 35 to 40 
days. In vitro bacterial viability studies indicated that the nanoparticles were effective at 
killing the intracellular bacteria, while empty nanoparticles did not exhibit any activity. 
These studies provide evidence for the utility of PLGA nanoparticle to deliver nafcillin 
effectively. 
0
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1.2.3 Fluoroquinolones 
 
1.2.3.1 Ciprofloxacin Loaded PLGA Nanoparticles 
Dillen et al. reported the use of Eudragit® as a co-polymer with PLGA in the formation of 
ciprofloxacin loaded nanoparticles (Figure 1.16).9 Utilizing either the RS 100 or the RL 
100 version of the Eudragit® product line (which differ by a small amount of 
trimethylammonioethyl methacrylate chloride), multiple ratios were used in the synthesis 
of these nanoparticles including 75:25, 50:50, and 25:75 (w/w) (Eudragit®:PLGA). 
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Figure (1.16). Eudragit® product line used in nanoparticle synthesis, and ciprofloxacin. 
 
The particles were synthesized using w/o/w emulsion solvent evaporation, and upon 
lyophilization (in the presence of the cryoprotectant mannitol) gave nanoparticles with 
resulting sizes between 125 and 250 nm. Ciprofloxacin loading was obtained between 60 
and 70% for all of the formulations used. Drug released studies showed between 15 and 
30 percent of the ciprofloxacin was released within 25 hours. The nanoparticles were 
tested against P. aeruginosa and S. aureus with the results shown in Table 1.3. 
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Table (1.3) Range of MIC values for ciprofloxacin loaded nanoparticles, in µg/ml. 
Treatment Bacterial Target MIC 24 h MIC 48 h 
Ciprofloxacin P. aeruginosa 0.11-0.22 0.11-0.22 
PLGA P. aeruginosa 0.26-0.28 0.27-0.53 
RL:PLGA 
100:0 
75:25 
50:50 
25:75 
P. aeruginosa  
0.31-0.62 
0.53-0.61 
0.26-0.34 
0.12-0.23 
 
0.31-1.20 
0.27-0.31 
0.26-0.34 
0.12-0.23 
RS:PLGA 
100:0 
75:25 
50:50 
25:75 
P. aeruginosa  
0.28-0.59 
0.56-0.64 
0.29-0.32 
0.22-0.46 
 
0.29-0.59 
0.28-0.63 
0.29-0.32 
0.22-0.46 
Ciprofloxacin S. aureus 0.18 0.35 
PLGA S. aureus 0.40-0.41 0.40-0.41 
RL:PLGA 
100:0 
75:25 
50:50 
25:75 
S. aureus  
0.23-0.47 
0.20-0.42 
0.40-0.52 
0.23-0.24 
 
0.23-0.47 
0.20-0.84 
0.20-1.03 
0.12-0.24 
RS:PLGA 
100:0 
75:25 
50:50 
25:75 
S. aureus  
0.22-0.43 
0.42-0.48 
0.23-0.48 
0.22-0.46 
 
0.42-0.86 
0.42-0.96 
0.23-0.87 
0.22-0.46 
 
 
It was found that the nanoparticles containing 75% PLGA gave activity close to that of 
the free drug, where as those nanoparticles with decreasing percentages of PLGA gave 
slightly higher MIC values. 
 
In 2008, Jeong et al. published their research involving the encapsulation of ciprofloxacin 
into PLGA nanoparticles and the corresponding in vitro and in vivo activity against 
Escherichia coli.10 Using a water/oil/water emulsion technique for synthesis of the 
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particles, it was shown that increasing amounts of PLGA and ciprofloxacin gave rise to 
larger nanoparticles, shown in Figure 1.17.  
 
 
Figure (1.17) Size distribution of nanoparticles with varying amounts of polymer and 
drug. 
 
The drug loading was also affected by the formulation quantities as the larger 
nanoparticles obtained a loading efficiency of 47.4% compared to 42.4% for the smaller 
nanoparticles. Drug release studies revealed that nearly all of the ciprofloxacin was 
released from each of the nanoparticles within 15 hours. Utilizing the smaller 
nanoparticles, in vitro testing showed that the nanoparticles had no effect on the bacteria 
when not loaded with ciprofloxacin. Free ciprofloxacin and the ciprofloxacin 
nanoparticles were able to kill the target bacteria, with free ciprofloxacin having better 
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activity. However, the nanoparticles fared much better in vivo than the free ciprofloxacin, 
showing a significant decrease in bacterial count in infected mice. 
 
1.2.3.2 Levofloxacin Loaded PLGA Nanoparticles 
Another antibiotic in the fluoroquinolone class is levofloxacin (Figure 1.18). In 2010, 
Cheow et al. published the use of PLGA and polycaprolactone (PCL) (Figure 1.19) 
nanoparticles as delivery systems in the treatment of E. coli biofilms in vitro.11  
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Figure (1.18) Levofloxacin 
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Figure (1.19) Polycaprolactone (PCL) 
 
Both types of nanoparticles were prepared using two different methods, nanoprecipitation 
with Pluronic F-68 (Figure 1.20) as the emulsifier, and emulsion solvent evaporation with 
poly(vinyl alcohol) as the emulsion stabilizer.  
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Figure (1.20) Pluronic F-68 
 
Both types of nanoparticles prepared via nanoprecipitation yielded smaller particle sizes 
than those created by emulsification solvent evaporation, 80 and 110 nm for PLGA and 
PCL nanoparticles, respectively. The emulsion solvent evaporation technique afforded 
PLGA nanoparticles with an average size 190 nm and PCL nanoparticles with an average 
diameter of 230 nm. PLGA nanoparticles fared better with regards to drug loading, 
obtaining an encapsulation efficiency of ~15 percent compared to ~5 percent for the PCL 
variety. Both types of nanoparticles created via nanoprecipitation showed huge burst 
release rates with nearly 100 percent of the drug released in the first day. Emulsification 
solvent evaporation prepared PLGA nanoparticles gave an initial release of 
approximately 80 percent after 1 day, and a second release within 3 days, with 100 
percent of the drug being released within 6 days. The similarly synthesized PCL 
nanoparticles released a significantly reduced amount of drug, with less than 50 percent 
leaving the particle after 1 day and ~75 percent after 6 days. The PLGA and PCL 
nanoparticles along with free levofloxacin were tested in vitro against E. coli biofilm 
cells and it was found that all three exhibited similar activity after 24 hours. In order to 
determine the efficacy of these nanoparticles against biofilms, a correlation between 
release and biofilm susceptibility was needed. On Day 1 each nanoparticle was able to 
kill approximately 99 percent of the biofilm cells. However, the authors describe that a 
portion of the remaining cells become tolerant to the drug. For the nanoparticles with a 
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slow release, these tolerant bacteria are able to multiply and obtain nearly the same 
number of colonies as were there before initial treatment on Day 2. The nanoparticles 
exhibiting a large burst release on Day 1 still maintained a significantly high 
concentration of drug in the media on Day 2, resulting in substantial inhibitory activity. 
Over the course of the next 4 days, all bacterial cells eventually are seen in equal amounts 
as they were pre-treatment as the concentration of the drug exponentially decreased. 
Based on the results, the authors claim that the ideal drug delivery system would be able 
to release a very large concentration of drug initially, and maintain a significant 
concentration of drug over a period of time in order to keep the antibiotic tolerant 
generations of cells under control beyond initial treatment. 
 
1.2.4 Macrolides 
 
1.2.4.1 Azithromycin Loaded PLGA Nanoparticles 
In an attempt to use nanoparticles as a treatment for intracellular chlamydial infections, 
Whittum-Hudson, et al, prepared PLGA nanoparticles loaded with azithromycin and 
rifampin.12 The nanoparticles were synthesized using the oil in water emulsion technique 
encapsulating coumarin-6, azithromycin, rifampin and a combination of the two afore 
mentioned antibiotics (Figure 1.21). 
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Figure (1.21) Coumarin 6 (left), azithromycin (middle) and rifampin (right) 
 
Nanoparticles containing coumarin-6 were shown to have a mean diameter near 260 nm, 
with the antibiotic loaded nanoparticles maintaining sizes similar to this. Drug loading 
results are shown in Table 1.4.  
Table (1.4) Drug loading results shown as % of drug in 100 mg of nanoparticle. 
Drugs Loaded Azithromycin Loading Rifampin Loading 
Azithromycin 4.2 + 0.7 - 
Rifampin  1.8 + 0.0 
Azithromycin and Rifampin 0.5 + 0.1 0.1 + 0.0 
 
 
When subjected to in vitro drug release studies it was found that the azithromycin 
achieved 80% release in 24 hours, whereas the rifampin was slower, with a release of 
60% in the first 8 hours, but not obtaining 100% release until after 7 days. Coumarin-6 
nanoparticles were used to determine cellular uptake into chlamydial inclusions, and 
through live microscopy it was found that the nanoparticles do indeed make their way 
into the cell. When tested against the bacteria it was found that the drug loaded 
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nanoparticles were more efficient at killing the bacteria than the requisite antibiotic, in all 
cases, including the dual loaded nanoparticle. 
 
Nokhodchi’s group also explored the association of azithromycin into PLGA 
nanoparticles in their efforts to study the nanoparticle’s anti-Salmonella activity.13 They 
synthesized the nanoparticles using nanoprecipitation with varying ratios of azithromycin 
to polymer (1:3, 1:2, 1:1) in order to determine differences in encapsulation efficiencies, 
dissolution profiles, and antibiotic activity, shown in Table 1.5 
Table (1.5) Encapsulation efficiencies and particle sizes of nanoparticle formulations 
used. 
Drug to Polymer Ratio Encapsulation Efficiency (%) Particle Size (nm) 
1:1 50.5 + 3.4 252 + 5 
1:2 66.8 + 2.8 230 + 7 
1:3 78.5 + 4.2 212 + 4 
 
 
According to the dissolution studies, it was found that the nanoparticle with the highest 
percentage of polymer released the drug the slowest. The 1:3 (drug:polymer) 
nanoparticles released 70% of the drug in 262 minutes, compared to that of the 1:1 ratio 
releasing the same percentage of drug in 143 minutes. The nanoparticles were evaluated 
against S. typhi, with the data shown in Figure 1.22. While the different formulations do 
not have an effect on the antibacterial activity, the data clearly shows that the particles 
enhance the activity of azithromycin. 
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Figure (1.22) Minimum inhibitory concentrations of nanoparticles compared to free drug 
against S. typhi.  
 
1.2.4.2 Clarithromycin Loaded PLGA Nanoparticles 
Mohammadi et al. reported the encapsulation of clarithromycin into PLGA nanoparticles 
in 2011 (Figure 1.23), in order to evaluate the system against Staphylococcus aureus, in 
vitro.14  
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Figure (1.23) Clarithromycin 
 
Nanoprecipitation was used to synthesize the clarithromycin loaded nanoparticles, 
including PVA as the emulsion stabilizer. Various formulations of varying ratios of drug 
to PLGA were used to prepare the nanoparticles. The effects of these differing ratios on 
the physical characteristics of the particles can be seen in Figures 1.24 and 1.25.  
 
 
Figure (1.24) Encapsulation efficiencies for clarithromycin loaded PLGA nanoparticles 
0
10
20
30
40
50
60
70
80
90
1:1 (Drug:Polymer) 1:2 (Drug: Polymer) 1:3 (Drug:Polymer)
En
ca
ps
ul
at
io
n 
Ef
fic
ie
nc
y 
(%
) 
27 
 
 
 
Figure (1.25) Particle sizes for clarithromycin loaded PLGA nanoparticles 
 
It can be seen that as the ratio of polymer is increased, the amount of drug encapsulated 
increases and the size of the particles decrease. Drug release experiments showed that 
after 24 hours the 1:1 formulation released the most drug, over 90 percent, with the 1:3 
formulation releasing nearly 70 percent. All formulations observed significant burst 
release accounting for over half of all drug incorporated with the nanoparticle. 
Antibacterial activity was also evaluated for the nanoparticles, Figure 1.26, 
demonstrating that the nanoparticles increase the efficacy of clarithromycin against S. 
aureus, however, the differing ratios of drug to polymer does not affect the MIC values. 
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Figure (1.26) Minimum inhibitory concentrations of clarithromycin loaded nanoparticles 
against S. aureus 
 
1.2.5 Rifamycin 
 
1.2.5.1 Rifampin/Rifampicin Loaded PLGA Nanoparticles 
Several studies involving the use of PLGA nanoparticles to deliver rifampicin have been 
published over the last 5 years (Figure 1.27). In 2007, Esmaeili et al. reported the 
preparation of these particles, along with the corresponding antibacterial activity against 
Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Bacillus subtilis 
as a preliminary study towards the treatment of Mycobacterium tuberculosis. 
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Figure (1.27) Rifampicin 
 
The nanoparticles were created using emulsification solvent diffusion with PVA as the 
stabilizing agent. A multitude of drug to polymer ratios was used in the different 
formulations with all of the resulting particles obtaining mean diameters between 200 and 
260 nm. In order to obtain the highest possible drug loading, the PVA amounts were 
tuned in order to study the effects on encapsulation. The authors reported a maximum 
encapsulation efficacy of 5.08 %. The drug release profile was determined for two of the 
formulations; with both giving an observable burst release followed by release of most of 
the remaining drug after 5 hours. Antibacterial testing was performed and it was found 
that the nanoparticles gave better activity than the free rifampicin against MRSA, 0.002 
µg/mL vs 0.008 µg/mL, and S. aureus, 0.002 µg/mL vs 0.008 µg/mL. The rifampicin 
loaded nanoparticles performed as well as the free drug against B. subtilis, with both 
giving a MIC value of 0.06 µg/mL. While the amount of drug loading of rifampicin was 
minor in regards to this nanoparticle system, the antibacterial activity of the drug was 
significantly improved when incorporated into these nanoparticles.  
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In 2009 Ohashi et al. described their progress towards nanoparticle treatment of 
tuberculosis by creating an aerosol delivery system using rifampicin loaded PGLA 
nanoparticles in mannitol microspheres.15  
 
 
Figure (1.28) Preparation of rifampicin loaded PLGA nanoparticles in mannitol 
microspheres. A. Rifampcin/PLGA acetone/methanol solution. B. Aqueous solution of 
mannitol. 
 
This system was created using a four-fluid nozzle spray drier in which compressed air 
(two points of entry), a rifampicin/PLGA acetone methanol solution, and a mannitol 
aqueous solution, are sprayed into a single focal point (nozzle) to create droplets of 
nanoparticles (Figure 1.28). Upon drying and collection, these particles were found to 
have a mean diameter between 1.3 and 2.7 µm. Rifampicin/PLGA nanoparticles were 
also created without the mannitol microspheres using a two-fluid nozzle approach. These 
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were found to be between 157 and 330 nm in size. The nanoparticles dispersed in the 
mannitol microspheres averaged 213 nm. In vitro uptake of the microspheres and 
nanoparticles were studied in order to see if the alveolar macrophages would incorporate 
the particles. Using coumarin-6 as the fluorescent probe, the authors were able to 
demonstrated that 47.1 % of the microspheres were taken up by the cells, along with 13.5 
% of the nanoparticles. In vivo uptake studies showed that the rifampicin loaded 
nanoparticle containing microspheres were taken up by the cells at about 4 percent after 1 
hour and increasing to 9.3 percent after 4 hours. This research suggests that inhalable 
nanoparticles (in this case enclosed within mannitol microspheres) could potentially be 
viable treatments for tuberculosis.  
 
Around the same time, Sung et al. published their work on self-assembled rifampicin 
PLGA nanoparticles as a pulmonary drug delivery system to potentially treat 
tuberculosis.16 The authors used the solvent evaporation method to synthesize these 
nanoparticles, using PVA as the emulsifier, resulting in nanoparticles with an average 
diameter of 195 nm, and comprised of 13.5 % rifampicin. Similar to Ohashi’s work, these 
were incorporated into larger microspheres created with an aqueous solution of L-leucine 
(Figure 1.29) via a two fluid nozzle spray dryer using 40 or 80 % of nanoparticles by 
weight, named PNAP40 and PNAP80 respectively.  
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Figure (1.29) L-leucine 
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The resulting microspheres were found to have an average diameter of 4.2 µm for both 
formulations. Nanoparticle-free microspheres containing rifampicin were also created 
and were shown to be 2.7 µm in size 39.1 % drug. Release studies were performed on all 
microspheres and they demonstrated a large initial burst release of nearly 80 percent, 
followed by minimal release afterwards over a period of eight days. The microspheres 
and free drug were all tested for the rifampicin levels in lung tissue and bronchoalveolar 
lavage components in order to see the concentration of drug 8 hours after treatment. 
PNAP40 and PNAP80 all showed a significant improvement over the free drug and 
nanoparticle free microspheres with regards to both tissues tested.  
 
These studies represent significant progress towards utilizing rifampicin loaded PLGA 
nanoparticles as a treatment option for tuberculosis, and offer important research towards 
the field of inhalable nanoparticle delivery systems. 
 
1.2.6 Other Antibiotics 
 
1.2.6.1 Carvacrol Loaded PLGA Nanoparticles 
In 2011, Cellini’s group reported the use of PLGA nanoparticles to deliver the essential 
oil component carvacrol (Figure 1.30) in order to disturb bacterial biofilms.17  
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Figure (1.30): Carvacrol 
 
Using phosphatidylcholine as the surfactant, the nanoparticles were synthesized using the 
solvent displacement method to obtain particles with a mean diameter of ~209 nm. 
Carvacrol was incorporated into the nanoparticles with a respectable encapsulation 
efficiency of 26%. Release studies indicate 95% of the drug is released after 24 hours, 
however, 60% of the drug underwent a burst release after 3 hours. The nanoparticles were 
tested against Staphylococcus epidermidis biofilms using rheological measurements. 
PNAP40 and PNAP80 both demonstrated significant improvement over the free drug and 
nanoparticle free microspheres. The results from this experiment give evidence that 
carvacrol nanoparticles may interfere with the structure of bacterial biofilms, via 
reduction of elasticity and mechanical stability, which could allow for better activity of 
accompanying antibacterial treatments.  
 
1.2.6.2 Chloramphenicol Loaded PLGA Nanoparticles 
In an effort to characterize the ability of PLGA nanoparticles to adequately deliver 
chloramphenicol (Figure 1.31), Halder et al. published the synthesis of chloramphenicol 
loaded nanoparticles.18 
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Figure (1.31) Chloramphenicol 
 
Using emulsification solvent evaporation to create the nanoparticles, two different types 
of particles were made, using poly(vinyl alcohol) (PVA) or polysorbate 80 (PS-80) 
(Figure 1.32) in order to stabilize the particles. 
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Figure (1.32) PVA (left) and PS-80 (right) 
 
Chloramphenicol loaded PVA PLGA nanoparticles gave sizes ranging from 10 to 70 nm, 
with the PS-80 variant yielding larger particles with average diameters from 40 to 120 
nm. For both variants, the authors were able to achieve an encapsulation efficiency of 65 
to 66 percent. In order to determine in vivo bio distribution, radiolabeling of the 
nanoparticles was required with 99mTc, obtaining radiolabeling efficiencies between 76 
and 97%. The radiolabeled nanoparticles were found to be less apt to be taken up by 
tissues than the free drug, and accumulated in a high concentration in the liver. As 
chloramphenicol is normally used due to its ability to pass the blood brain barrier (BBB), 
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the authors were delighted to find that the PS-80 variant of the particles maintained a 
higher concentration in the brain than that of the free drug or the PVA nanoparticles. The 
distribution studies also indicated that the PS-80 drug loaded nanoparticles were found to 
be significantly less concentrated in the bone marrow than the free drug, being the main 
downside of using chloramphenicol clinically. This data suggests that PS-80 PLGA 
nanoparticles are suitable carriers of chloramphenicol due to the higher BBB transport 
capabilities and lessened bone marrow uptake.  
 
1.2.6.3 Violacein Loaded PLGA Nanoparticles 
Martins et al. published the use of PLGA nanoparticles as delivery vehicles for the 
antibiotic violacein (Figure 1.33) and the corresponding antibacterial activity against 
MRSA, E. coli, and Salmonella enterica.19 
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Figure (1.33) Violacein 
 
Using nanoprecipitation, PLGA nanoparticles with Pluronic F-68 as the surfactant were 
synthesized and found to have average diameters between 116 and 130 nm. After 
purification and lyophilization, 87 % of violacein was incorporated into the particles. 
Violacein was found to have been completely released after 172 hours with no significant 
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burst release observed. The minimum inhibitory concentrations of each of the 
nanoparticles were evaluated against a multitude of bacteria, shown in Figure 1.34.  
 
 
Figure (1.34) Minimum inhibitory concentrations for violacein loaded PLGA 
nanoparticles. 
 
While both the free drug and the drug loaded nanoparticles were shown to not target E. 
faecalis, E. coli, and S. enterica at appropriate levels, the nanoparticles dramatically 
increased the efficacy of violacein against all strains of S. aureus and S. epidermidis. The 
authors also showed that over longer periods of time, the drug loaded nanoparticles were 
more effective at preventing growth post-exposure, with bacterial growth inhibited up to 
36 hours after treatment, compared to 10 to 14 hours for the free drug. 
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1.3 Polyacrylate Nanoparticles 
 
1.3.1 Poly(alkyl cyanoacrylate) Nanoparticles 
In 1979 Couvreur et al. reported novel poly(methyl cyanoacrylate) and poly(ethyl 
cyanoacrylate) nanoparticles prepared via anionic emulsion polymerization (Figure 1.35) 
with Tween 20 as the surfactant.20  
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Figure (1.35) Poly(alkyl cyanoacrylate) polymers 
 
Particle sizes were determined via scanning electron microscopy, yielding a size of 200 
nm. The nanoparticles were found to contain highly porous innards, an advantage for 
drug loading, and sorption of fluorescein at varied pH values from 2 to 8. The 
poly(methyl cyanoacrylate) particles were able to incorporate 50% of the fluorescein and 
the poly(ethyl cyanoacrylate) particles took in 65% for pH between 2 and 4. At higher 
pH, the fluorescein left the particle. When utilizing the anticancer drug daunorubicin, the 
drug was sorbed at high pH levels and minimal sorption was seen at lower pH.  
 
While this information was presented in a very short communication in the late 70s, the 
PACA nanoparticles became very prominent in the nanoparticle field, especially with 
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regards to drug delivery. This section describes the use of these particles as antibiotic 
drug carriers.  
 
1.3.1.1 Aminoglycosides/Polypeptides 
 
1.3.1.1.1 Actinomycin D Loaded PACA Nanoparticles 
In 1980 Kante et al. studied the tissue distribution of  [3H]actinomycin D delivered by 
poly(butyl cyanoacrylate) nanoparticles (Figure 1.36). 21 The authors used emulsion 
polymerization to incorporate the drug into the nanoparticles which had an average radius 
of 260 to 290 nm.  
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Figure 1.36 Actinomycin D 
 
It was determined that 65% of the drug was incorporated into the nanoparticle. Rats were 
injected with the drug loaded nanoparticles and a control group was injected with free 
drug, with the amounts of drug found in various tissues shown in Figure 1.37.  
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Figure (1.37) Concentrations of drug in various tissues. 
 
The nanoparticles drastically increased drug uptake in the spleen and kidneys compared 
to the uptake of free drug by 44 fold and 64 fold, respectively.  
 
1.3.1.1.2 Gentamicin Loaded PACA Nanoparticles 
The use of radiolabeled gentamicin (Figure 1.9) loaded poly(butyl cyanoacrylate) 
nanoparticles to determine macrophagic and hepatocytic uptake was reported in 1998 by 
Zhang et al.22 Several formulations were used to create the nanoparticles for this study, 
all involving the use of emulsion polymerization with the effect s of the different 
formulations on particle size shown in Figure 1.38. 
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Figure (1.38) Particle sizes of nanoparticle formulations 
 
The nanoparticles and free radiolabeled drug were each incubated with mouse peritoneal 
macrophages for 30 minutes, after which radioactivity was measured in order to compare 
the uptake of the radiolabeled drug. It was found that all of the nanoparticles were able to 
increase drug uptake over the free drug, with the best results achieving around a 5 fold 
increase over the free drug. Drug uptake in rat hepatocytes was also tested for the 5 
nanoparticles and the free drug. The results were similar in the fact that the same 
nanoparticle formulation that gave the best increase of macrophagic uptake, the small 
Dextran 70 particles, also performed well in this assay with the increased uptake into 
macrophages by 26.73 fold for 1 hour, 8.03 after 12 hours, and a 7.63 fold increase after 
24 hours (versus the free drug). These results indicate that surfactant and particle size are 
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both important factors with regards to the endocytosis of these particles in different cells 
in the body.  
 
1.3.1.1.3 Netilmicin Loaded PACA Nanoparticles 
Fresta and Puglisi published their work in 1994 on the incorporation of the 
aminoglycoside netilmicin (Figure 1.39) into poly(ethyl cyanoacrylate) (PECA) and 
poly(isobutyl cyanoacrylate) (PICA) nanoparticles.23  
 
O
O
O
O
HNHO
HO
NH
H2N
OH
H2N
H2N  
Figure (1.39) Netilmicin 
 
Three types of nanoparticle formulations were used with each of the polymer cores. The 
first method involved the common place emulsion polymerization technique where the 
drug is involved in the synthesis from the very beginning. In order to promote adsorption, 
the second method involved the synthesis of drug free nanoparticles and after 
lyophilization the empty nanoparticles were resuspended  in an aqueous solutionsof drug. 
The third method was similar to the first; however, after acquiring the suspension, the 
nanoparticles were lyophilized. Nanoparticles were made using these 3 techniques with 
both Tween 80 and Pluronic F68 as surfactants.  
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Drug incorporation studies were done on all 12 types of nanoparticles synthesized shown 
in Figure 1.40. 
 
 
Figure (1.40) Drug entrapment studies 
 
The third method of nanoparticle preparation resulted in the highest drug association, to 
which the authors attributed these results to the freeze drying process, providing a more 
suitable environment for stronger interactions between the polymer core and the drug. 
Correlations between original drug concentrations and final drug association was also 
evaluated the first method of nanoparticle preparation, shown in Figure (1.41), which 
clearly shows a correlation between increased initial drug concentration and increased 
drug associated with the nanoparticle. 
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Figure (1.41) Effects of initial amounts of drug on final drug association with 
nanoparticles 
 
1.3.1.2 β-Lactams 
 
1.3.1.2.1 Amoxicillin Loaded PACA Nanoparticles 
In 2001, Fontana et al. studied amoxicillin (Figure 1.42) loaded poly(ethyl cyanoacrylate) 
nanoparticles in an effort to determine how PEG coating affects particle size, drug release 
and phagocytic uptake.24 
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Figure (1.42) Amoxicillin 
 
The authors utilized the emulsion polymerization technique to create the drug loaded 
nanoparticles using Pluronic F68 as the surfactant, and varying weights of  PEG were 
also incorporated with the effects on particle size and drug incorporation shown in Table 
1.6.  
Table (1.6) Effects of varying PEG on particle size and amoxicillin association of 
nanoparticles 
PEG (%w/v) Size (nm) Drug Incorporated (%w/w) 
0 320 + 12 5.5 + 0.15 
2 (PEG 600) 280 + 8 3.5 + 0.11 
2 (PEG 2000) 230 + 15 7.5 + 0.21 
2 (PEG 4000) 220 + 10 8.1 + 0.23 
 
 
With regards to in vitro drug release, it was shown that the higher the molecular weight 
of the PEG, the more amoxicillin was released in PBS buffer at a pH of 7.4. However, 
when the study was done in human plasma, the opposite trend was observed where the 
PEG free nanoparticles released the most drug, after 240 minutes. The authors believe 
that this phenomenon can be described by the presence of esterases in the human plasma, 
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which may be prevented from degrading the polymer core if the nanoparticles are 
protected with PEG. Murine macrophages were used to determine how the different 
formulations affected uptake of the nanoparticles. As the PEG weight increased, 
macrophagic uptake significantly diminished, 50% for PEG 2000 and 70% for PEG 4000. 
The nanoparticles that did not use PEG were completely taken up by the macrophages 
after 30, 60 and 90 minutes. Drug release from the nanoparticles with PEG 4000 was also 
studied in the presence and absence of urease, which resulted in a larger amount of drug 
being released in 240 minutes when the nanoparticles were in presence of urease than 
those in the absence of the esterase. This suggests that the polymeric core is indeed 
broken down by esterases, resulting in increased drug release.  
 
1.3.1.2.2 Ampicillin Loaded PACA Nanoparticles 
An incredible amount of research has been done on the loading of PACA nanoparticles 
with the β-lactam ampicillin (Figure 1.43).  
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Figure (1.43) Ampicillin 
 
In 1988, Youssef et al. described their studies on how effective ampicillin loaded 
poly(isohexyl cyanoacrylate) (PIHCA) nanoparticles would be in treating mice infected 
with Listeria monocytogenes.25 Through emulsion polymerization, nanoparticles with 
average sizes of 172 nm (drug free) and 187 nm (drug loaded) synthesized, with 90 % of 
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the ampicillin (2 mg/ml used in formulation) loaded into the nanoparticles. Bioactivity of 
drug free nanoparticles, drug loaded nanparticles, free drug, along with drug free 
nanoparticles mixed with free ampicillin was examined via determination of bacterial 
counts in the livers and spleens of infected mice. The nanoparticles failed to exhibit any 
real activity with regards to reducing the bacterial counts in the spleen compared to the 
other treatments, however, drug loaded nanoparticles demonstrated superior activity in 
the liver, and being roughly 20 fold more active than free ampicillin.  
 
Shortly after this study, the same group published the use of these nanoparticles in 
treating mice infected with Salmonella typhimurium C5.26 The results of the in vivo study 
are shown in Table (1.7). 
Table (1.7) In vivo mice study evaluating the efficacy of ampicillin loaded nanoparticles 
               Survivors (%) 
Treatment Dose of 
Drug 
(mg/mouse) 
# of 
Doses 
5 8 10 15 20 30 40 60 
Untreated   100 40 0      
Empty NPs 0 3 100 40 0      
Free Drug 0.8 3 100 100 60 40 0    
Free Drug 16 3 100 100 100 40 0    
Free Drug 32 3 100 100 100 100 100 100 100 100 
Free Drug 32 1 100 100 40 20 0    
Free Drug 64 1 0        
NP Drug 0.8 3 100 100 100 100 100 100 100 100 
NP Drug 0.8 1 100 100 100 100 100 100 100 100 
NP Drug 0.4 1 100 100 70 50 0    
Empty NP and 
Free Drug 
0.8 3 100 100 60 20 0    
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While the free drug (32mg, 3 doses) was able to keep all of the mice alive after day 60, 
the authors report that the ampicillin loaded nanoparticles were also able to accomplish 
this using a significantly smaller amount of antibiotic.  
 
A year later, Seijo et al. created ampicillin loaded poly(isobutyl cyanoacrylate) (PIBCA) 
and ampicillin loaded PIHCA nanoparticles with average diameters below 50 nm, via the 
use of emulsion polymerization, with Pluronic F68 as the surfactant, with the particle 
sizes shown in Table 1.8.27  
 
Table (1.8) Particle sizes of PIBCA and PIHCA nanoparticles 
Concentration of Monomer 
(µl/ml) 
Isobutyl Cyanoacrylate 
Size (nm) 
Isohexyl Cyanoacrylate 
Size (nm) 
1 31+ 7 26 + 5 
2 33 + 7 32 + 4 
5 35 + 8 35 + 9 
10 45 + 14 40 + 14 
20 56 + 7 40 + 15 
 
 
Drug loading studies were done and it was shown that up to nearly 70 µg of ampicillin 
per mg of PIBCA nanoparticles was obtained when using 2 mg of ampicillin in the 
synthesis of the particles. Drug release studies confirmed that the presence of an esterase 
increases the release of ampicillin, by about 10 percent after 8 hours. With respectable 
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drug loading and release characteristics, these smaller nanoparticles allow for a 
broadening of biological applications. 
 
Fattal et al. continued their work on poly(isohexyl cyanoacrylate) nanoparticles in 1991 
in order to compare ampicillin bound particles to ampicillin loaded liposomes.26b, 28 
Liposomes were synthesized with the use of soybean phosphatidylcholine, cholesterol, 
phosphatidylglycerol and ampicillin, and the PIHCA nanoparticles were synthesized by 
emulsion polymerization. Particle size and drug loading for the drug loaded liposome and 
drug loaded nanoparticle are shown in Table 1.9.  
 
Table (1.9) Particle size and ampicillin loading for liposomes and PIHCA nanoparticles 
 Liposomes Nanoparticles 
Size (nm) 208 + 70 187 + 13 
Drug Loading (%) 4.6 90 
 
 
Studies revealed that before lyophilization, the liposomes had incorporated 100 percent of 
the ampicillin and that the majority of the drug was lost during the freeze drying process. 
Ampicillin release from the nanoparticles was slower than the liposome counterpart, with 
less than 20 percent released after 2 hours. The liposomes, however, underwent a small 
burst release in the first 30 minutes, releasing nearly 60 percent of the loaded ampicillin, 
and over 80 percent after 2 hours. The nanoparticles and liposomes were evaluated for 
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their antimicrobial activity against Bacillus subtilis, with the zones of inhibition shown in 
Figures 1.44 and 1.45. 
 
 
Figure (1.44) Zones of inhibition of drug loaded nanoparticles against B. subtilis. 
 
 
Figure (1.45) Zones of inhibition of drug loaded liposomes against B. subtilis 
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The ampicillin loaded PIHCA nanoparticles exhibited slightly smaller zones of inhibition 
than the free drug, and the treatment of the particles with esterases before introduction to 
bacteria did not enhance activity. The liposomes fared much better, resulting in activities 
relatively equal to those of the free drug, even after drug release was encouraged with a 
pretreatment of Triton x 100. The high drug loading involved with the PIHCA 
nanoparticles and the steady slow release indicates that these particles could be suitable 
for long term drug release, and that the liposomes offer a different mode of action 
involving a significant amount of drug release early on.  
 
In 1992 Forestier continued work on the antimicrobial activity of ampicillin loaded 
PIHCA nanoparticles against Listeria monocytogenes in order to better understand if the 
nanoparticles facilitating intracellular uptake of the drug.29 In vitro experiments involving 
the growth of the bacteria in mouse peritoneal macrophages showed that while initially 
the untreated macrophages and those treated with the free drug, empty nanoparticles and 
the drug loaded nanoparticles all had the same bacterial count, the drug loaded 
nanoparticles exhibited a major enhancement in antibacterial activity after 30 hours 
compared to the other treatments. In order to determine if the nanoparticles did in fact 
facilitate intracellular penetration, the infected macrophages were then subjected to initial 
treatment as done before, and then treated again at 24 hours. The initial treatment was 
intended to kill extracellular bacteria, upon which the treatment at 24 hours would be 
used to eradicate the intracellular bacteria. It was found that when free drug was added at 
24 hours to the infected macrophages treated with free drug initially or with drug loaded 
nanoparticles initially, bacterial counts continued to increase, suggesting that while the 
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extracellular media may be cleared of bacteria, but the intracellular bacteria continued to 
thrive. Contrarily, when the drug loaded nanoparticles were added at the 24 hour mark to 
the same pretreated macrophages, bacterial counts continued to decrease, suggesting that 
the nanoparticles are effective intracellular delivery vehicles. Couvreur’s group followed 
up on this experiment with their report providing visual evidence for the intracellular 
infiltration suggested in the previous work.30 Through transmission electron microscopy 
and confocal microscopy, Pinto-Alphandary et al. demonstrated that not only did 
antibacterial activity come from direct bacterial interactions with the nanoparticles, but 
also through migration of free ampicillin previously released in the macrophage. Balland 
et al. used radiolabeled ampicillin to investigate the in vitro interaction between the 
nanoparticles and two types of murine macrophages, peritoneal and J774.31 Macrophagic 
ampicillin uptake was evaluated for both free drug and drug loaded nanoparticles. For the 
peritoneal macrophages the drug loaded nanoparticles were able to increase ampicillin 
uptake by up to 24 fold. The uptake was nearly the same with regards to the infected 
peritoneal macrophages, with up to a 20 fold increase over the free drug. The retention of 
the drug in the intracellular medium was also evaluated. Both drug loaded nanoparticles 
and free drug were tested, and it was shown that ampicillin introduced via the PIHCA 
nanoparticles maintained a 25 fold increase in drug concentration over ampicillin 
introduced as free drug. Antimicrobial activity for the nanoparticles was surprisingly 
similar to that of the free ampicillin against S. typhimurium. The authors suggest that this 
could be due to a lack of interaction between the nanoparticles and the bacterial 
phagosomes that carry esterases able to hydrolyze the polymer core, and thereby release 
the encapsulated drug. Another possible explanation given is that once the drug has 
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diffused from the particle, it becomes ionized, preventing introduction into the infected 
phagosomes. Two years later, Balland et al. released a follow up study evaluating the 
intracellular distribution of radiolabeled ampicillin in the same two macrophages 
previously studied using the same bacteria for both short-term and long-term treatment.32 
While after 2 to 4 hours of incubation, the radiolabeled ampicillin was located throughout 
the cytoplasmic medium and inside vacuoles, after 12 hours of incubation the 
radiolabeled drug was shown to be in high concentrations within spherical bodies, 
described to be β-lactam induced cell wall modifications of the bacteria, indicating that 
the drug was in fact delivered intracellularly via the nanoparticles.  
 
1.3.1.3 Fluoroquinolones 
 
1.3.1.3.1 Ciprofloxacin Loaded PACA Nanoparticles 
In 1997, Fawaz et al. described the loading of poly(isobutyl cyanoacrylate) nanoparticles 
with ciprofloxacin (Figure 1.16) and the characteristics of those particles.33 Various 
particle sizes were obtained at different pH values. At a pH of 1.5, particles with an 
average mean diameter of 1020 nm were obtained, while those synthesized at pH 4.0 
were 594 nm in size. The ideal pH was determined to be 2.75 as it gave acceptable sized 
nanoparticles (195 nm) and the best polydispersity index (0.023) yielded particles with 
average diameters of 195 nm. The synthesis of empty nanoparticles gave an average size 
of 143 nm, and the particle size was unchanged during the subsequent experiments to 
adsorb ciprofloxacin at varying pH values. The effects of ciprofloxacin concentration on 
the size of the particles were also evaluated. PIBCA nanoparticles encapsulating 
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ciprofloxacin did not demonstrate any real change in size until the drug concentration 
was increased to 1.5 mg/mL. At this point, the size dramatically increased as 
concentration increased, resulting in particle sizes of nearly 700 nm at 2 mg/mL. 
Concentrations evaluated higher than 2 mg/mL resulted in a very gradual decrease in 
particle size. Particles that had adsorbed ciprofloxacin, meanwhile, were very tolerant of 
drug concentration with no appreciable change in particle size observed. The effects of 
varying pH on drug loading were also evaluated for both the encapsulation and the 
adsorption method. Between pH values of 1.0 and nearly 3.0, the efficiency of 
encapsulation of ciprofloxacin increased, however, this was followed by a leveling off 
which lead to a decrease of drug encapsulation starting approximately at pH 4.0. Drug 
loading via adsorption increased gradually as the initial concentration increased. Altering 
the original concentration of ciprofloxacin during encapsulation or adsorption had a 
similar impact on both versions of the drug loaded nanoparticles. The nanoparticles that 
incorporated ciprofloxacin via encapsulation tolerated well increased drug concentration 
by encapsulating more of the drug. As concentrations grew higher, the adsorption rates 
did not increase very rapidly however. Ultimately, with a drug concentration of 90 
mg/100 mL the nanoparticles were able to encapsulate ~160 µg/mg nanoparticle, while 
less than 40 µg/mg nanoparticles was adsorbed. Drug release from both types of 
nanoparticles was evaluated as well in the presence and the absence of esterases. 
Ciprofloxacin adsorbed onto the nanoparticles underwent rapid release, with all of the 
drug being released within one hour. With the enzyme, the degradation of the polymer 
was facilitated, reducing the time for 100% drug release to 15 minutes. Ciprofloxacin that 
had been encapsulated never achieved complete release. While in the presence of the 
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esterase, the drug was released from the nanoparticle at a much higher rate than in 
absence of esterase. However, after 12 hours the release was relatively the same, and 
after 24 hours between 75 and 81% of ciprofloxacin had been released from the 
nanoparticles.  
 
In 1998, Page-Clisson et al. reported the synthesis and characteristics of ciprofloxacin 
loaded poly(2-ethylbutyl cyanoacrylate) nanoparticles (Figure 1.46). 
 
O O
NC  
Figure (1.46) (2-Ethylbutyl cyanoacrylate) monomer 
 
Two types of PEBCA nanoparticles were used in this study, one prepared via emulsion 
polymerization with various surfactants/colloid stabilizers, and one prepared similar to 
the nanoprecipitation method. It was determined that only half of the drug was 
encapsulated within the nanoparticles. Drug release studies indicated that after 6 hours 
only 22.3% of the drug had been removed from the particles, and only 62.7% after 48 
hours. The authors also report that the presence of esterases did not affect drug release. In 
vitro antimicrobial activity was also evaluated against S. typhimurium and it was shown 
that the particles did not enhance ciprofloxacin’s activity.  
 
Later that year, Page-Clisson et al. continued their work on ciprofloxacin loaded PEBCA 
nanoparticles and evaluated the particles’ antibacterial activity against Salmonella 
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through the use of both in vivo and ex vivo assays.34 Ciprofloxacin loaded nanoparticles 
were injected intravenously into mice in order to determine how the nanoparticles 
affected drug distribution within the body. Ciprofloxacin concentrations in the liver and 
spleen were found to be 5.75 fold and 3.2 fold higher, respectively, than concentrations of 
drug delivered without nanoparticle delivery. In vivo antibacterial activity was evaluated 
for ciprofloxacin and 2 other drugs. Both free ciprofloxacin and a mixture of free 
ciprofloxacin and ciprofloxacin loaded nanoparticles were shown to be active during late 
stage infections, however, they seemed to have the same level of activity.  
 
Yordanov et al. published their work on the loading of ciprofloxacin into poly(n-butyl 
cyanoacrylate) nanoparticles to evaluate the nanoparticles’ antibacterial activity against 
Escherichia coli.35 Using emulsion polymerization and Pluronic F-68 as the surfactant, 
ciprofloxacin loaded PBCA nanoparticles were synthesized with an average mean 
diameter of 240 nm. The researchers used 1H NMR spectroscopy to confirm entrapment 
of ciprofloxacin. The effects of varying concentrations of ciprofloxacin used in the 
formulation on the encapsulation efficiency were also studied. The use of 1 mg/mL of 
ciprofloxacin gave the highest encapsulation efficiency, slightly less than 45 percent, and 
as the concentration of drug was increased, the encapsulation efficiency was shown to 
decrease. The ciprofloxacin loaded nanoparticles were also subjected to drug release 
studies at varying pH values, with release being the most efficient at pH 7.4 and least 
efficient at a pH of 5.6. Concurrently, the authors studied the effects of pH on the 
degradation of the nanoparticles. The nanoparticles underwent degradation the swiftest at 
a pH of 7.4 and slowest at pH 5.6, appropriately correlating to the drug release studies. It 
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is important to note that complete release of ciprofloxacin was never achieved and under 
the optimized conditions 30% of the drug remained in the nanoparticles. In vitro 
antibacterial testing against E. coli revealed that the PBCA nanoparticles themselves were 
not active against the bacteria, and the nanoparticles did not enhance nor diminish the 
native activity of ciprofloxacin since the drug loaded nanoparticles had the same MIC 
value as free ciprofloxacin.  
 
1.3.1.3.2 Moxifloxacin Loaded PACA Nanoparticles 
Kisich et al. reported the loading of moxifloxacin into poly(butyl cyanoacrylate) 
nanoparticles in order to evaluate the antibacterial activity against Mycobacterium 
tuberculosis in macrophages (Figure 1.47).36  
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Figure (1.47) Moxifloxacin 
 
Using emulsion polymerization as the method of synthesis, nanoparticles were created 
with an average mean diameter of 418 nm and achieved 44.6% encapsulation of 
moxifloxacin. Drug release studies were carried out on the drug loaded nanoparticles and 
a large burst release of approximately 55% of the encapsulated moxifloxacin was 
released initially followed by a negligible release over the next 24 hours. Infected 
macrophages were treated with both moxifloxacin loaded nanoparticles and free 
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moxifloxacin. It was clearly demonstrated that the moxifloxacin delivered via 
nanoparticles was found to be in the macrophage at much higher concentrations than the 
free drug, as much as 3 fold after 2 hours. It was also shown that moxifloxacin delivered 
via nanoparticles were expelled from the macrophages at a reduced rate compared to that 
of the free drug. The antibacterial activity of the moxifloxacin loaded nanoparticles 
compared to free moxifloxacin was evaluated against M. tuberculosis within 
macrophages and it was found that the drug loaded nanoparticles did not fare as well as 
the free drug. The authors state that this type of assay would be ideal for assessing 
activity close to that of an in vivo assay, in which the highest concentration of the drug is 
relatively short lived until the next administration of the drug.In order to truly determine 
if the nanoparticles in fact decrease the activity of the fluoroquinolone, a pulsed exposure 
experiment was performed in which infected macrophages were treated with free drug or 
drug loaded nanoparticles for 2 hours. After lysing of the macrophages from the pulsed 
study, the researchers determined that the nanoparticles did in fact increase the activity of 
moxifloxacin.  
 
1.3.2 Poly(styrene-co-butylacrylate) Nanoparticles 
 
1.3.2.1 β-Lactams 
 
1.3.2.1.1 N-Thiolated β-Lactam Loaded Polyacrylate Nanoparticles 
In 2000, Turos et al. reported the synthesis of novel N-thiolated β-lactams (Figure 
1.48).37  
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Figure (1.48) N-thiolated β-lactams 
 
In 2002 it was found that these compounds possessed antibacterial activity against 
Staphylococcus aureus and, later in 2006, against Bacillus anthracis.38 However, Turos’ 
group observed that the high lipophilic character of these compounds created a significant 
barrier in terms of treatment plausibility. In 2007, Turos et al. reported the synthesis of 
drug-conjugated polyacrylate nanoparticles as delivery vehicles and the anti-MRSA 
activity of the corresponding β-lactam loaded nanoparticles.39  
 
In order to covalently attach the drugs to the polymer backbone, the authors synthesized 
acrylated versions of the lactams (Figure 1.49) and by employing similar methodology, 3 
other acrylated lactams were synthesized, with the structures of these shown in Figure 
1.50.  
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Figure (1.49) Synthesis of acrylated β-lactams 
N
O
O Cl
O
SCH3
O
O
O
O
N
O
H3CO
SCH3
O
O
N
O
O
SCH3
O
O
O
 
Figure (1.50) Other acrylated β-lactams 
 
With the acrylated compounds in hand, the nanoparticles were synthesized via emulsion 
polymerization. The acrylated lactam, styrene, and butyl acrylate monomers were 
polymerized using a water soluble radical initiator and sodium dodecyl sulfate was used 
as the surfactant (Figure 1.51).  
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Figure (1.51) Synthesis of drug bound poly(styrene-co-butylacrylate) nanoparticles 
 
The resulting particles had an average diameter between 30 and 50 nm. Each lactam 
loaded nanoparticle was tested in vitro against both S. aureus and MRSA, along with the 
corresponding free β-lactams, shown in Figure 1.52.  
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Figure (1.52) Minimum inhibitory concentrations of drug loaded nanoparticles and the 
corresponding β-lactams. 
 
The nanoparticles themselves, sans drug, were not effective at killing either bacteria, 
however, when loaded with the drugs, the minimum inhibitory concentrations were 
between 4 and 8 fold better than the corresponding free drugs. 
 
1.3.2.1.2 Penicillin Loaded Polyacrylate Nanoparticles 
Later in 2007 the Turos laboratory published their work on covalently bound penicillin 
nanoparticles in the attempt to restore the activity of the drug against MRSA.40 
Synthesizing the nanoparticles in the same method previously described, several 
acrylated penicillins (Figure 1.53) were used as monomers to produce emulsion 
polymerized (styrene-butylacrylate) nanoparticles with a diameter between 25 and 40 nm.  
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Figure (1.53) Acrylated penicillins used as monomers for emulsion polymerization 
 
Penicillin G and a penicillin G ester were also used (Figure 1.54), however, since these 
two drugs did not contain the required functionality for incorporation into the polymer 
back bone, the drugs were encapsulated within the particles.  
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Figure (1.54) Penicillin G (left) and penicillin ester (right) 
 
In vitro MIC testing of the nanoparticles revealed that all of the drug loaded particles 
were able to kill both S. aureus and MRSA at equal concentrations, indicating the 
nanoparticles did in fact deliver the drug to the bacterial target, Figure 1.55. 
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Figure (1.55) Minimum inhibitory concentrations of drug loaded nanoparticles and 
penicillin G.  
 
Kirby-Bauer assays showed that the nanoparticles protected the penicillin from 
degradation by penicillinases.  
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1.3.2.3 Carbohydrate Derivatized Penicillin, Ciprofloxacin, and N-Thiolated β-
Lactam Loaded Polyacrylate Nanoparticles 
Abeylath et al. reported poly(styrene-co-butylacrylate) nanoparticles as a means to 
deliver monosaccharide-bound penicillin and ciprofloxacin drugs (Figure 1.56) and 
proceeded to ascertain their in vitro activity against MRSA and B. anthracis.41 
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Figure (1.56) Glycosylated antibiotic acrylates 
 
With these rather large glycosylated acrylates, the authors showed that it was possible to 
covalently incorporate the attached antibiotics into the polymer core of the nanoparticle 
utilizing emulsion polymerization. Somewhat surprisingly, these particles were found to 
have similar sizes to the previous work, with an average diameter of 40 nm. Figure 1.57 
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shows the MIC values that were obtained for the three nanoparticle emulsions and the 
corresponding monomers on S. aureus, MRSA, and B. anthracis. 
 
 
Figure (1.57) Minimum inhibitory concentrations of the drug loaded nanoparticles and 
the corresponding drug monomers. Penicillin G was not tested against B. anthracis. 
 
It can be seen that the clactam loaded nanoparticle was more efficient at killing both 
staphylococci than the corresponding free (acrylate monomer) drugs. However, neither 
gave activity against B. anthracis. The ciprofloxacin loaded nanoparticles showed no 
difference in activity compared to the free (acrylate monomer) drug in all 3 bacteria 
tested. In contrast, the third acrylate monomer carrying penicillin, and the corresponding 
drug loaded nanoparticles, gave no activity against the three microbes. More research 
needs to be done regarding the release characteristics of these covalently attached drugs 
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from the nanoparticle, to understand why the nanoparticle increased efficacy of the N-
thiolated β-lactam, but not derivatized ciprofloxacin or penicillin.  
 
1.4 Chitosan Based Nanoparticles 
Chitosan has been used as a polymeric core for nanoparticles for quite a while. 
Synthesized by deacylating chitin (Figure 1.58), this polymer has been shown to have a 
variety of medicinal uses, including its antihemorrhagic properties currently in use by 
many as an emergency bandaging solution.42 
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Figure (1.58) Synthesis of chitosan from chitin (poly(N-acetyl glucosamine)) 
 
While the polymer itself has some antibacterial properties, the use of chitosan as the 
polymeric core for non-metallic nanoparticle antibiotic delivery is relatively 
underdeveloped.43 However, over the last 5 years, several reports have described the 
incorporation of antibiotics into chitosan nanoparticles. 
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1.4.1 β-Lactams 
 
1.4.1.1 Amoxicillin Loaded Chitosan Nanoparticles 
In 2009, Ramteke et al. reported the use of amoxicillin, clarithromycin and omeprazole 
loaded chitosan-glutamate nanoparticles to assess the efficacy of these systems in treating 
Helicobacter pylori.44 The chitosan polymer was first modified via coupling to glutamic 
acid (Figure 1.59) and the resulting chitosan-glutamate was used to synthesize drug 
loaded nanoparticles via ionotropic gelation (described in Chapter 1). Using a modified 
protocol of the chitosan-glutamate synthesis, α-(L)-fucose derivatized nanoparticles were 
also created in order to test whether or not the fucose derivatized particles would have 
higher affinity towards H. pylori, given prior evidence that this bacterium contains 
glycoprotein receptors on the cell surface. 
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Figure (1.59) Synthesis of chitosan-glutamate 
 
Particle sizes and drug loading for the nanoparticles are shown in Table 1.10.  
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Table (1.10) Particle size and drug loading for chitosan-glutamate and fucose-conjugated 
chitosan-glutamate nanoparticles. 
Nanoparticle Particle Size (nm) Drug Entrapment (%) 
Chitosan-Glutamate 544.4 + 12.02 88.5 + 2.8 (Amoxicillin) 
91.1 + 2.3 (Clarithromycin) 
58.4 + 3.7 (Omeprazole) 
Fucose-Conjugated 874.97 + 25.49  
 
It was also shown that while the amoxicillin underwent degradation at pH 3, it was 
protected while inside the nanoparticles. Drug release studies show that the fucose 
derivatized chitosan nanoparticles released the drugs at a slower rate than the fucose-free 
chitosan-glutamate counterpart, achieving roughly 80% release after 8 hours. The fucose-
free nanoparticles released 100% of the entrapped amoxicillin after 5 hours. Both 
clarithromycin and omeprazole loaded nanoparticles demonstrated similar release 
profiles. To evaluate whether or not the bacteria did exhibit a preference for the 
fucosylated nanoparticles, agglutination studies were carried out. It was indeed found that 
aggregation was observed for the fucose nanoparticles but not seen for the fucose-free 
chitosan-glutamate nanoparticles. In vitro evaluation of the free drugs and drug loaded 
nanoparticles was performed with that data represented in Figure 1.60. 
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Figure (1.60) Eradication rate of H. pylori by free drugs and drug loaded nanoparticles 
 
In vivo experiments were also performed with Swiss albino mice infected with H. pylori. 
After infection, the stomachs of the mice were removed and homogenized with the results 
shown in Table 1.11.  
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Table (1.11) Number of viable colonies and in vivo clearance rate of mice infected with 
H. pylori. ENP: Empty nanoparticles; FD: Free drugs; CGNP: Chitosan-glutamate 
nanoparticles; FCCGNP: Fucose-conjugated chitosan-glutamate nanoparticles. 
Treatment Dose of 
Amoxicillin 
(mg/kg) 
Dose of 
Clarithromycin 
(mg/kg) 
Dose of 
Omeprazole 
(mg/kg) 
Number of 
Colonies 
(log CFU) 
In vivo 
Clearance 
Rate 
Control    7.94 + 1.72 0/6 
ENP    7.77 + 0.76 0/6 
FD 6.69 
13.39 
26.78 
53.57 
2.2 
4.4 
8.9 
17.8 
0.175 
0.35 
0.71 
1.42 
7.83 + 0.65 
7.02 + 0.93 
6.65 + 0.5 
4.36 + 1.32 
0/6 
1/6 
2/6 
2/6 
CGNP 6.69 
13.39 
26.78 
53.57 
2.2 
4.4 
8.9 
17.8 
0.175 
0.35 
0.71 
1.42 
2.62 + 0.60 
2.18 + 0.48 
1.00 + 1.20 
0.73 + 0.80 
0/6 
0/6 
3/6 
3/6 
FCCGNP 6.69 
13.39 
26.78 
53.57 
2.2 
4.4 
8.9 
17.8 
0.175 
0.35 
0.71 
1.42 
1.89 + 0.95 
1.30 + 1.06 
0.89 + 0.72 
0 
1/6 
3/6 
3/6 
6/6 
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Triple therapy formulations of free drugs, fucose-free drug loaded nanoparticles, and 
fucose derivatized drug loaded nanoparticles were used and only high concentrations of 
the fucose derivatized drug loaded nanoparticles were able to obtain 100% clearance 
rates, indicating that the particles do in fact increase the efficacy of these drugs as anti H. 
pylori agents. Chang et al. also incorporated amoxicillin into chitosan-glutamate 
nanoparticles, which were used in the formation of pH sensitive hydrogels, and were able 
to show increased protection of the drug at gastric pH levels and increased drug 
interaction with H. pylori infection sites, in vitro.45  
 
1.4.1.2 Ceftriaxone Loaded Chitosan Nanoparticles 
Ceftriaxone (Figure 1.61) has also been incorporated into chitosan nanoparticles to 
determine how the nanoparticles affect antibacterial activity against Salmonella 
typhimurium.46 
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Figure (1.61) Ceftriaxone 
 
The researchers used tripolyphosphate (TPP) ionic crosslinking and coacervation 
(discussed earlier) to prepare several ceftriaxone loaded nanoparticles by varying the 
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intial drug concentration used in the formulation. The encapsulation efficiencies and 
particle sizes are shown in Table 1.12. 
 
Table (1.12) Encapsulation efficiencies and particle sizes of ceftriaxone loaded chitosan 
nanoparticles 
Ceftriaxone Concentration 
(mg/ml) 
Encapsulation Efficiency 
(%) 
Particle Size 
(nm) 
0.1 50.3 202 
0.5 47.3 208 
1.0 45.5 210 
2.0 44.7 221 
 
 
In vitro drug release studies were performed with nanoparticle formulations using varied 
starting concentrations of ceftriaxone. In this case, drug release was increased for those 
particles synthesized with higher drug concentrations. All drug loaded particles 
experienced a burst release within the first hour. Nanoparticls created with 0.1 mg/mL 
drug were shown to release less than 50% of the drug after 96 hours, however, those with 
1.5 mg/mL ceftriaxone released nearly 90% after 96 hours. Drug loaded nanoparticles 
were found to not have any substantial hemolytic effects towards red blood cells and 
were deemed nontoxic towards Caco-2 and J774.2 cells at reasonable conditions. 
Fluorescently labeled nanoparticles were incubated with Caco-2 and J774.2 cells in order 
to determine cellular uptake, and after 30 minutes of incubation, it was seen via confocal 
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microscopy that the nanoparticles were found inside the cells. In vitro antibacterial 
testing was performed using the two cell lines mentioned earlier that had been infected 
with Salmonella, and the drug loaded nanoparticles were found to increase the activity of 
the drug against the bacteria, attributed to enhanced intraphagocytic delivery of the drug 
by the nanoparticles.  
 
1.4.2 Fluoroquinolones 
 
1.4.2.1 Ciprofloxacin Loaded Chitosan Nanoparticles 
In 2007 a comparison of various nanoparticle carriers loaded with ciprofloxacin was 
reported by Jain and Banerjee, in which ciprofloxacin was loaded into nanoparticles 
comprised of gelatin, albumin, or chitosan along with solid lipid nanoparticles.47 The 
chitosan nanoparticles were synthesized as previously described with TPP ionic 
crosslinking and had an average mean diameter between 247 and 322 nm. Modifying the 
amount of ciprofloxacin in the original formulation had an effect on drug loading with 
chitosan nanoparticles. The drug entrapment efficiencies ranged 70.1 and 111 %. The 
authors chose a formulation that gave less than optimal drug loading, ~35%, but a 
favorable zeta potential of +22.95 eV. The ciprofloxacin loaded chitosan nanoparticles 
underwent an immediate burst release, followed by a gradual release of the drug, 
reaching nearly complete release at approximately 96 hours. While no biological activity 
was reported, the acceptable drug loading and release profile of ciprofloxacin loaded 
chitosan nanoparticles suggests the need for further research to determine how these 
particles affect antibacterial activity, along with that of other fluoroquinolone antibiotics. 
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1.4.3 Poly/Glycopeptides 
 
1.4.3.1 Nisin Loaded Chitosan Nanoparticles 
Interestingly, nisin loaded chitosan/alginate nanoparticles were created with the purpose 
of increasing antibacterial efficacy against Staphylococcus aureus in raw and pasteurized 
milk.48 The chitosan nanoparticles were synthesized using a 1:1 (w:w) mixture of 
chitosan and sodium alginate (Figure 1.62), and had sizes between 50 and 250 nm, with a 
mean average diameter of 205 nm.  
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Figure (1.62) Sodium Alginate 
 
Nisin was incorporated into the chitosan-alginate nanoparticles with a loading efficiency 
of 90 to 95%. After 4 hours of dialysis in PBS at 37 °C, more than 85% of the entrapped 
nisin was released, followed by tapering of leakage afterwards. The nisin loaded 
nanoparticles were evaluated for antibacterial activity against S. aureus using pasteurized 
and raw milk with. When compared to the free drug, the drug loaded nanoparticles 
demonstrated equal activity as the free drug after 24 hours of incubation; however, after 
48 hours the nisin loaded nanoparticles continued to exact bacterial inhibition, whereas 
the free drug did not. Both the free drug and the drug loaded nanoparticles fared well in 
the raw milk assay as well, with the same trend observed for the pasteurized milk seen in 
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the raw milk after 14 hours continuing through 24 hours. This study presents an 
interesting avenue for nanoparticle delivered antibiotic use in food safety and should be 
explored further.  
 
1.4.3.2 Vancomycin Loaded Chitosan Nanoparticles 
In 2010, vancomycin entrapped in chitosan nanoparticles was shown to have promising 
activity against vancomycin-resistant S. aureus.49 The polymeric core for these particles 
is folic acid tagged carboxymethyl chitosan, whose synthesis is shown in Figure (1.63).  
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Figure (1.63) Synthesis of carboxymethyl chitosan (CMC) tagged with folic acid. a) 
NaOH, ClCH2COOH, b) Boc2O, CHCl3, c) DCC, folic acid d) CF3COOH, e) EDC, 
CMC 
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The chitosan nanoparticles had an average size of 210 nm, and after loading of 
vancomycin, the particles had an average mean diameter of 260 nm. NIH 3T3 cells 
treated with the nanoparticles showed no toxicity, effects. The vancomycin loaded 
nanoparticles were effective at inhibiting vancomycin-susceptible S. aureus with 
minimum inhibitory concentrations 50% lower than that of the free drug. When evaluated 
against vancomycin-resistant S. aureus, the nanoparticles also fared well, exhibiting MIC 
values 98 lower than that of the free drug. This study shows again the effectiveness that 
nanoparticles can have on prolonging the life of antibiotics to which bacteria have 
acquired resistance. 
 
1.5 Conclusions 
This chapter discussed the use of PLGA, polyacrylate, and chitosan nanoparticles as 
antibiotic delivery systems against a wide array of different bacterial targets and in 
various settings, including in vitro, in vivo, and ex vivo. Nanoparticles have been proven 
to increase the antibacterial activity of various antibiotics even against resistant strains. 
Drugs can be protected to maintain a longer presence in the body. Tissue/organ uptake of 
antibiotics can be increased through the use of nanoparticle delivery, as well as 
improving intracellular penetration to get drugs to bacteria inside human cells. With 
increasing rates of resistance and an ever slowing rate of antibiotic discovery, 
antibacterial nanoparticle therapy provides an avenue of potential utility in the long battle 
against bacterial infections. 
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CHAPTER 2 
 
SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF N-ACYL CIPROFLOXACINS 
 
 
2.1 Introduction 
Our laboratory’s research has focused on the development of novel antibiotics, and the 
delivery of these and other antimicrobial compounds through the use of nanoparticles, 
specifically those composed of polyacrylates. Our repeated failed attempts at 
incorporating ciprofloxacin into these polyacrylate nanoparticles led us to consider 
attempts to “tune” ciprofloxacin in order to encapsulate it into the nanoparticle system. 
Complementary to this goal, we were also interested to determine how this tuning may 
affect the antimicrobial activity. 
 
Quinolones have been a mainstay in antibiotic treatment since the early 1960’s with the 
discovery of nalidixic acid, a compound used for the treatment of urinary tract infections 
(Figure 2.1). 
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Figure (2.1) Nalidixic Acid 
 
Multiple generations of quinolones have been synthesized to date; however, 
fluoroquinolones continue to maintain the largest presence with regards to clinical use, 
with ciprofloxacin, ofloxacin and moxifloxacin reported as the most prescribed in 2002 
(Figure 2.2).50 
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Figure 2.2 Ciprofloxacin (left), ofloxacin (middle) and moxifloxacin (right) 
 
Our basis for the structural modifications of ciprofloxacin was to increase the 
lipophilicity in hopes of increasing the hydrophobic interactions within the particle, 
without diminishing antimicrobial activity. The most apparent way to incorporate various 
lipophilic moieties was to attach different acyl groups on the piperizinyl nitrogen (Figure 
2.3). 
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Figure 2.3 N-acyl ciprofloxacin 
 
Several of the N-acyl ciprofloxacins were reported in the patent literature in the mid 
1980’s and were evaluated briefly for antibacterial activity.51 In 2009 Azema et al. 
reported the use of several N-acyl ciprofloxacins as antitumor agents.52 They reported 
increasingly higher MIC values against cancer cell lines as the lipophilicity (logP) of the 
N-acyl ciprofloxacins increased. Aside from these two instances very little work has been 
done on expanding the library of N-acyl ciprofloxacins beyond a few compounds, or to 
evaluate the antibacterial activity on a larger scope. This chapter discusses studies on the 
synthesis, antibacterial activity, and mechanism of action of N-acyl ciprofloxacins. 
 
2.2 Synthesis 
In order to evaluate the effects of lipophilicity, 18 N-acyl ciprofloxacin derivatives were 
synthesized as shown in Figures 2.4 and 2.5.  
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Figure (2.4) Linear N-acyl ciprofloxacins 
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Figure (2.5) Branched N-acyl ciprofloxacins 
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Originally, synthesis of the N-acyl ciprofloxacins was performed by treating a suspension 
of ciprofloxacin HCl salt and triethylamine in dichloromethane with the requisite acid 
chloride (Figure 2.6).52 
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Figure (2.6) Our original synthesis of N-acyl ciprofloxacins 
 
However, it was found that after acylation, a subsequent amidation at the carboxylic acid 
could sometimes occur yielding minute amounts of the “dimer”, 19, whose structure was 
determined via LCMS.  
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Figure (2.7) Dimer 19 
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While this undesired adduct was not present in the majority of cases, the corresponding 
available acid anhydrides were utilized instead, resulting in no formation of 19 (Figure 
2.8), with yields of N-acyl ciprofloxacin products being between 32 and 96%. 
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Figure (2.8) Use of the acid anhydride for the synthesis of the N-acyl ciprofloxacins  
 
2.3  Antibacterial Activity 
In order to determine how the lipophilic “tuning” of the N-acyl ciprofloxacins affected 
biological activity, they were tested against a variety of Gram-positive and Gram-
negative bacteria. Modified Kirby-Bauer assays, minimum inhibition concentration 
assays, DNA gyrase activity assay, spontaneous mutation frequency assay, and 
intracellular viability assays were all used to determine how the lipophilicity affects these 
drugs compared to that of the parent N-protic compound. 
 
2.3.1  N-Acyl Ciprofloxacin Antibacterial Activity Against Gram-Positive Bacteria 
Staphylococcus aureus (both methicillin-resistant and methicillin-susceptible), Bacillus 
anthracis, and Enterococcus faecalis were chosen as the Gram-positive bacteria and the 
bioactivity was tested by Whittney Burda in Dr. Les Shaw’s laboratory. All experiments 
were performed in triplicate. 
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2.3.1.1 Staphyloccocus aureus 
Initially, modified Kirby-Bauer disk diffusion assays were performed on the CBD-635 
strain of MRSA (USA100), shown in Table 2.1.53 When compared to the parent 
ciprofloxacin, 14 of the 18 compounds had bigger growth inhibition zones against 
MRSA, with the strongest, 5, having a 36 mm zone of inhibition. Ciprofloxacin gave a 
zone of 6 mm along with 3, 7, 15, and 18, which corresponds to no growth at all. There 
was no observable trend for these results.  
 
Table (2.1) Zones of inhibition for N-acyl ciprofloxacins against MRSA* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
MRSA (CBD-635) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
Methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
24 
20 
6 
30 
36 
30 
6 
22 
34 
26 
6 
30 
33 
31 
35 
28 
22 
6 
6 
*All data shown in mm. Values of 6 represent no growth inhibition. All experiments done 
in triplicate. 
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With moderate activity from the disk diffusion assays, minimum inhibition 
concentrations were determined for the compounds and it was found that none of the 
analogues were effective at killing the bacteria. USA 100 is known to be a very resistant 
strain and in order to obtain activity against MRSA, a less resistant strain was selected, 
ATCC 43300. Along with MRSA, activity against the MSSA strain SH1000 was also 
evaluated. These results are shown in Table 2.2. The N-acyl ciprofloxacins were found to 
be active against both bacteria. With regards to the methicillin-susceptible strain, 
compounds 4, 10, and 12 demonstrated better activity than the control, whereas 
analogues 1, 8, 9, 14, 15, and 16 were as active as ciprofloxacin with an MIC value of 10 
ug/mL. Against the methicillin-resistant strain, compounds 4, 12, 13 and 14 displayed 
significantly enhanced activity with MIC values of 1 µg/mL, while ciprofloxacin 
inhibited growth at 15 µg/mL. Compounds 1, 8, and 9 exhibited slightly increased 
activity compared to ciprofloxacin, at 10 µg/mL. 
 
Spontaneous mutation frequency assays were peformed on a few compounds, 1, 2,  9, and 
14, in order to see how the analogues compared to ciprofloxacin with regards to rate of 
mutation against MSSA. Compounds 1, 9, and 14 all had MIC values of 10 µg/mL, while 
2 had a value of 40 µg/mL. Table 2.3 shows the results. 
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Table (2.2) Minimum inhibition concentrations against MRSA and MSSA* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
MRSA 
 
 
 
 
 
 
MSSA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
Methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
10 
100+ 
100+ 
1 
25 
100+ 
25 
10 
10 
100+ 
100+ 
1 
1 
1 
100+ 
100+ 
100+ 
100+ 
15 
10 
40 
100+ 
7.5 
20 
25 
25 
10 
10 
10 
10 
100+ 
10 
5 
25 
100+ 
7.5 
25 
10 
*All data shown in µg/mL. All experiments done in triplicate. 
 
Table (2.3) Spontaneous mutation frequency results for N-acyl ciprofloxacins* 
Compound 1.0x MIC 1.5x MIC 2.0x MIC 2.5x MIC 
1 
2 
9 
14 
Ciprofloxacin 
90 
ND 
Lawn 
Lawn 
ND 
41 
ND 
Lawn 
7 
ND 
101 
ND 
Lawn 
4 
ND 
0 
0 
Lawn 
0 
551 
*All data shown represents number of colonies. Lawn = Complete covering of plate with 
bacterial cells. ND = Not Determined. All experiments done in triplicate. 
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For compound 9, we saw very rapid mutation frequencies as bacterial colonies 
encompassed the entire plate at all four concentrations. 1 and 14 gave rise to 232 and 11 
resistant colonies, respectively. Starting from a total inoculum of 1.7 x 1010, compound 
1’s spontaneous mutation rate is 7.3 x 10-7. 14 fared significantly better than the others 
with a spontaneous mutation rate of 1.08 x 10-9. 1, 2, and 14 all yielded no resistant 
colonies at 2.5x MIC when compared to 551 for that of ciprofloxacin, giving it a 
spontaneous mutation rate of 1.02 x 10-6. 
 
2.3.1.2 Bacillus anthracis and Enterococcus faecalis 
The Sterne strain of B. anthracis54 and the DS16 strain of E. faecalis55 were used for the 
disk diffusion assays. These experiments were performed by Whittney Burda in Dr. Les 
Shaw’s laboratory. All experiments were done in triplicate. 
 
From the disk diffusion assays (Table 2.4) compound 9 was the only N-acyl ciprofloxacin 
derivative to demonstrate activity below that of the parent ciprofloxacin with a zone of 6 
mm against B. anthracis. 1 was the most active of all the analogues with an average zone 
of inhibition of 89 mm.  
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Table (2.4) Zones of inhibition for N-acyl ciprofloxacins against B. anthracis* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
B. anthracis 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
89 
86 
86 
80 
77 
71 
65 
55 
6 
65 
72 
81 
67 
57 
80 
70 
80 
49 
42 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
were performed in triplicate. 
 
The N-acyl ciprofloxacin library can be further segregated into two types of N-acyl 
derivatives, those with linear acyl chains (1-9) and those with branched (10-18). When 
comparing the data of the linear acyl derivatives there is a clear trend between 
lipophilicity/chain length and activity (Figure 2.9). The drugs are organized by calculated 
logP as determined via Chemdraw (Version 7.0). 
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Figure (2.9) Zones of inhibition of linear acyl derivatives against B. anthracis. Organized 
by increasing calculated logP. 
 
The N-acyl ciprofloxacins also fared well against E. faecalis in the disk diffusion assays, 
shown in Table 2.5. Compounds 1, 2, 3, 4, 5, 6, 10, 11, 12, and 14 were found to have 
better activity than ciprofloxacin, with 1 being the most active.  
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9
Zo
ne
s o
f I
nh
ib
iti
on
 (m
m
) 
N-acyl ciprolfloxacins 
90 
 
Table (2.5) Zones of inhibition for N-acyl ciprofloxacins against E. faecalis* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
E. faecalis 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
48 
46 
40 
39 
38 
36 
29 
23 
6 
28 
26 
22 
33 
45 
25 
32 
44 
6 
31 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
done in triplicate. 
 
Figure 2.10 shows a scatter of zones of inhibition plotted against calculated logP. It can 
be seen that an overall general trend of increased lipophilicity (log P) leads to decreased 
activity, which is enhanced while evaluating the straight chained analogues (Figure 2.11). 
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Figure (2.10) Zones of inhibition of all N-acyl ciprofloxacins against E. faecalis versus 
logP 
  
Figure (2.11) Zones of inhibtion of the linear (left) and branched (right) N-acyl 
derivatives against E. faecalis, organized by increasing calculated logP. 
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2.3.2 N-Acyl Ciprofloxacin Antibacterial Activity Against Gram-Negative Bacteria 
In order to assess the activity of the N-acyl ciprofloxacin library against Gram-Negative 
bacteria, disk diffusion assays were performed on Bartonella and E. coli along with 
minimum inhibitory concentrations on Bartonella henselae. The Bartonella testing was 
done in Dr. Anderson’s lab (USF College of Medicine) while the E. coli testing was 
performed in Dr. Shaw’s laboratory (USF Department of Cellular Microbiology). 
 
2.3.2.1 Bartonella  
Disk diffusion assays were performed on B. henselae (ATCC 49882), B. quintana 
(ATCC VR358), B. elizabethae (F9251), and B. vinsonii (ATCC VR152).56 11 was the 
only N-acyl ciprofloxacin to exhibit better activity than the positive control against B. 
henselae, however, 2 was as active as ciprofloxacin and 1 was almost as potent. The 
results are shown in Table 2.6.  
 
An overall trend can be seen where activity is inversely related to lipophilicity, as seen in 
Figures 2.12 and 2.13. 
 
 
 
 
 
 
 
93 
 
 
 
Table (2.6) Zones of inhibition for N-acyl ciprofloxacins against B. henselae* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
B. henselae 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
52 
56 
34 
38 
31 
28 
16 
6 
10 
12 
14 
33 
37 
41 
15 
62 
40 
21 
56 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
done in triplicate. 
 
 
94 
 
 
Figure (2.12) Comparison of in vitro bioactivity of all N-acyl ciprofloxacins against B. 
henselae, organized by increasing calculated logP. 
 
 
Figure (2.13) Comparison of in vitro bioactivity of the linear (left) and branched (right) 
subsections against B. henselae, organized by increasing calculated logP. 
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Curiously, against B. quintana the parent ciprofloxacin showed no inhibition of growth, 
whereas most of the N-acyl ciprofloxacins displayed activity, shown in Table 2.7. 
Compound 2 was the strongest inhibitor of growth with a zone of 58 mm. Only 1, 15, and 
16 failed to inhibit any growth.  
 
Table (2.7) Zones of inhibition for N-acyl ciprofloxacins against B. quintana* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
B. quintana 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
Methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
6 
58 
29 
35 
30 
20 
14 
11 
11 
6 
6 
17 
24 
27 
7 
36 
33 
7 
6 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
were done in triplicate. 
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Aside from several trend breaking compounds, the overall relationship between 
increasing lipophilicity and lower activity can still be seen against B. quintana (Figures 
2.14 and 2.15). 
 
 
Figure (2.14) Comparison of in vitro bioactivity of all N-acyl ciprofloxacins against B. 
quintana, organized by increasing calculated logP. 
 
Figure (2.15) Comparison of in vitro bioactivity of the linear (left) and branched (right) 
N-acyl derivatives against B. quintana, organized by increasing calculated logP. 
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The N-acyl ciprofloxacins failed to surpass ciprofloxacin with regards to inhibiting B. 
elizabethae growth. Compound 1 was equally effective as ciprofloxacin, and 2 was 
almost as equal, as shown in Table 2.8. 
 
Table (2.8) Zones of inhibition for N-acyl ciprofloxacins against B. elizabethae* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
B. elizabethae 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3) C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
58 
57 
42 
35 
30 
20 
14 
12 
9 
12 
6 
26 
32 
32 
8 
37 
36 
13 
58 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
were performed in triplicate. 
 
As was shown in the previous two species of Bartonella, the more lipophilic N-acyl 
ciprofloxacins demonstrated smaller zones of inhibition (Figures 2.16 and 2.17). 
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Figure (2.16) Zones of inhibition of all N-acyl ciprofloxacins against B. elizabethae, 
organized by increasing calculated logP. 
 
Figure (2.17) Zones of inhibition of the linear (left) and branched (right) subsections 
against B. elizabethae, organized by increasing calculated logP. 
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The final Bartonella species that the N-acyl ciprofloxacins were evaluated against was B. 
vinsonii, with the disk diffusion assay results shown in Table 2.9. 2 was the only 
compound to demonstrate a larger zone than ciprofloxacin. Compound 4 gave a zone of 
57 mm, which was close to the 58 mm for the control.  
The structure-activity against B. vinsonii follows the same trend as before, shown in 
Figures 2.18 and 2.19. 
 
Table (2.9) Zones of inhibition for N-acyl ciprofloxacins against B. vinsonii* 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
B. vinsonii 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3)C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
ND 
60 
44 
57 
21 
22 
15 
14 
9 
15 
6 
25 
30 
33 
10 
40 
36 
12 
58 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
were performed in triplicate. 
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Figure (2.18) Zones of inhibition of all N-acyl ciprofloxacins against B. vinsonii, 
organized by increasing calculated logP. 
 
Figure (2.19) Zones of inhibition of the linear (left) and branched (right) subsections 
against B. vinsonii, organized by increasing calculated logP. 
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It can be clearly seen by evaluating the disk diffusion assay data from all of the 
Bartonella species that the N-acyl ciprofloxacins are active and as the lipophilic character 
of the drug increases, the activity decreases. Minimum inhibitory concentration assays 
were performed on B. henselae, and the values of each compound is shown in Table 2.10. 
Ciprofloxacin is reported to have an MIC value of 0.5 to 1 µg/mL.57 
 
Table (2.10) Minimum inhibition concentrations for N-acyl ciprofloxacins against B. 
henselae* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
B. henselae 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3)C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
ND 
0.5 
0.5 
5.0 
5.0 
10.0 
10.0 
10.0 
5.0 
ND 
5.0 
5.0 
0.8 
0.5 
1.0 
0.2 
ND 
0.2 
.05-1 
*All data shown in µg/mL. All experiments were performed in triplicate. 
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The trend that was observed for the disk diffusion assays was not well defined in the MIC 
assay. The MIC values of the N-acyl ciprofloxacin plotted against calculated logP is 
shown in Figure 2.20. 
 
Figure (2.20) MIC values of all N-acyl ciprofloxacins against B. henselae. versus logP. 
 
To further examine the analogues’ antibacterial activity, against Bartonella, we evaluated 
several of the compounds against Bartonella henselae in an intracellular assay done in 
Dr. Anderson’s laboratory. HMEC-1 cells were infected with B. henselae, after which 
gentamicin was used to kill any remaining extracellular bacteria.58 These cells were then 
incubated with compounds 1, 2, 3, 11, and 12, along with ciprofloxacin for 96 hours. As 
can be seen in Figure 2.21, after the 96 hour incubation, every compound tested resulted 
in the killing of the majority of the intracellular bacteria at 1 µg/mL. With 0.1 µg/mL 
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concentrations, the N-acyl ciprofloxacins killed more of the intracellular bacteria than 
ciprofloxacin. 
 
 
Figure 2.21 Percentage of colonies remaining post 96 hour incubation with N-acyl 
ciprofloxacins 
 
2.3.2.2 Escherichia coli 
The N-acyl ciprofloxacins were also evaluated against E. coli, D5Hα, via the modified 
disk diffusion assays in Dr. Shaw’s laboratory. These results, Table 2.11, show that 
several of the N-acyl ciprofloxacins, 1, 2, 3, 4, 6, and 10, demonstrated better in vitro 
activity than ciprofloxacin itself. Curiously, drugs 7, 9, 15, 16, 17, and 18 all failed to 
inhibit any growth.  
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Table (2.11) Zones of inhibition for N-acyl ciprofloxacins against E. coli* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
E. coli 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3)C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
60 
57 
48 
47 
30 
45 
6 
30 
6 
6 
6 
39 
33 
38 
6 
36 
51 
6 
43 
*All data is shown in mm. A value of 6 represents no growth inhibition. All experiments 
were performed in triplicate. 
 
When plotting the zones of inhibition against calculated logP (Figure 2.20), it is clear that 
the N-acyl ciprofloxacins yet again display the same activity trend with regards to 
increasing lipophilicity. 
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Figure (2.22) Zones of inhibition of all N-acyl ciprofloxacins against E. coli versus logP 
 
2.3.3 N-Acyl Ciprofloxacins and Eukaryotic Cells 
While it is important that potential antibacterial agents possess good antimicrobial 
activity, it is also incredibly important that these drugs do not target normal human cells. 
In order to confirm bacterial selectivity of the N-acyl ciprofloxacins, they were evaluated 
for cytotoxicity against the eukaryote S. cerevisiae, shown in Table 2.12. None of the N-
acyl ciprofloxacins showed any inhibition of growth, providing evidence that the N-acyl 
ciprofloxacins target bacteria specifically in the antiproliferation effects.  
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Table (2.12) Zones of inhibition for N-acyl ciprofloxacins against S. cerevisiae* 
 
 
 
 
 
 
Compound 
 
O
N
F
N
N
O
HO
R
O  
R 
 
 
 
 
 
 
S. cerevisiae 
1 
2 
3 
4 
5 
6 
7 
8 
9 
16 
15 
13 
14 
12 
17 
11 
10 
18 
Ciprofloxacin 
methyl 
ethyl 
propyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
nonyl 
CH(CH2CH3)CH2CH2 CH2CH3 
CH(CH2CH2CH3)2 
CH(CH2CH3)2 
CH(CH3)CH2CH2CH3 
C(CH3)2CH2CH3 
CH2 CH(CH3)C(CH3)3 
CH2CH(CH3)2 
C(CH3)3 
phenyl 
 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
*Data shown in mm. A zone of 6 mm represents no inhibition of growth. All experiments 
were performed in triplicate. 
 
 
2.3.4 Mechanism of Action of N-Acyl Ciprofloxacins 
It is well known that fluoroquinolones act on DNA synthesis, more specifically, on DNA 
gyrase and DNA topoisomerase IV.59 During replication, the gyrase is responsible for 
alleviating DNA strain while it is unwound. Quinolones bind to this DNA-Gyrase 
complex, stopping replication and cell growth. While this would not alone cause 
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bacteriocidal activity, this results in the release of DNA ends which are fatal to the 
bacterial cell, causing cell death.  
 
In order to determine whether or not the N-acyl ciprofloxacins use the same mechanism 
of action, the compounds’ ability to inhibit DNA gyrase from E. coli were evaluated in 
Dr. Anderson’s laboratory, shown in Figure 2.23.60 Compounds 1, 2, 5, 10, and 17 were 
all tested against a positive and negative control. The negative control contained no 
gyrase to aid in the conversion of relaxed DNA (R) to supercoiled DNA (S), whereas the 
positive control contained gyrase. It can clearly be seen that the conversion took place. 
All of the compounds inhibited DNA gyrase activity. It is shown that with higher 
concentrations of drugs, relaxed DNA is not converted to the supercoiled DNA. 
 
 
Figure 2.23 Effects of N-acyl ciprofloxacins 1, 2, 5, 10, and 17 on DNA gyrase activity. 
Concentrations of drugs tested in each series were 100, 50, 10 and 1.0 µg/mL. R: Relaxed 
DNA, S: Supercoiled DNA. 
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Further studies on the mechanism of action involving these compounds were done via 
DNA sequencing by Dr. Shaw’s laboratory. Utilizing the mutant colonies from the 
resistance studies of compounds 1 and 14, the Quinolone Resistance-Determining 
Regions of the DNA gyrase and topoisomerase were sequenced. If the N-acyl 
ciprofloxacins utilized the same mechanism of action as most fluoroquinolones, the gene 
sequencing would reveal mutations that are known to be responsible for fluoroquinolone 
resistance. This is what was observed. Sequencing revealed that S84L and E88K 
mutations were found in the DNA gyrase subunit gyrA and that S80Y and E84G 
mutations were found in the topoisomerase subunit grlA. Interestingly, the E84G 
mutation is somewhat rare, and has been documented for other fluoroquinolones, but not 
ciprofloxacin.61 
 
2.4 Conclusions and Future Directions 
With the original goal of synthesizing lipophilic ciprofloxacin derivatives for the 
inclusion into nanoparticles, we found that the N-acyl ciprofloxacins are in fact 
promising drug candidates. Against the CBD-635 strain of MRSA, nearly all of the 
compounds demonstrated better zones of inhibition than ciprofloxacin; however, the 
minimum inhibitory concentration assay gave no appreciable activity for these 
compounds. When tested against a less resistant MRSA strain (ATCC 43300), 4, 12, 13, 
and 14 gave significantly lower MIC values than ciprofloxacin. The N-acyl 
ciprofloxacins were found to have incredible activity against B. anthracis with some 
analogues nearly doubling the zone of inhibition given by ciprofloxacin. Evaluation of 
the drugs against E. faecalis resulted in compounds 1, 2, 3, 4, 5, 6, 10, 11, 12, and 14 
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bacterial growth more effectively than the parent drug. With regards to Gram-negative 
bacteria, the N-acyl ciprofloxacins also fared well. It was shown that against all of the 
Bartonella strains, various drugs were effective in the disk diffusion assays. This was 
particularly interesting in the case of B. quintana where ciprofloxacin had no zone of 
inhibition. In this case, the majority of the N-acyl ciprofloxacins did inhibit growth, with 
the most active compound, 2, maintaining a 58 mm zone of inhibition. The N-acyl 
ciprofloxacins were evaluated further against B. henselae via minimum inhibitory 
concentration assays and it was found that compounds 2, 3, 11, 12, 14, 17, and 18 were 
either more or as active as ciprofloxacin. It was also shown that the compounds were 
effective at killing intracellular B. henselae, with the N-acyl ciprofloxacins being more 
active than ciprofloxacin at lower concentrations. Against E. coli, several of the N-acyl 
ciprofloxacins gave larger zones of inhibition than ciprofloxacin. The N-acyl 
ciprofloxacins were found to encourage resistance at a significantly lower rate than 
ciprofloxacin with regards to MRSA, and it was shown through the DNA gyrase study 
along with DNA sequencing of the before mentioned resistant bacterial colonies that 
these drugs do in fact have the same mode of action as known quinolones via interference 
of DNA synthesis. It was also clearly shown that for most of the bacteria evaluated, 
antimicrobial activity is inversely related to the lipophilicity of the N-acyl ciprofloxacins.  
 
As these ciprofloxacin derivatives demonstrate activity against a broad range of bacteria, 
have lowered acquired resistance rates, and are inactive against eukaryotic cells, it is 
evident that they are promising antibacterial agents and should be explored further.  
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In addition to the studies presented above, current investigations in the laboratory are 
focused on the use of enantiomerically pure chiral ciprofloxacin analogues shown in 
Figure 2.24, in order to evaluate whether the antipodes have the same antimicrobial 
activity.  
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Figure 2.24 Chiral Ciprofloxacin Derivatives 
 
Along with this, we hope to see if the antipodes have different propensities to be 
incorporated into polyacrylate nanoparticles consisting of enantiopure acrylated 
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monomers in an effort to find differences in drug loading, drug release and antimicrobial 
activity.  
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CHAPTER 3 
 
THE USE OF N-ACYL CIPROFLOXAXINS IN STUDYING THE EFFECTS OF 
LIPOPHILICITY ON MOLECULAR CARRIER PROPERTIES OF POLY(VINYL 
BENZOATE) NANOPARTICLES 
 
 
3.1 Introduction 
Our attempts at incorporating the N-acyl ciprofloxacins into polyacrylate nanoparticles 
during emulsion polymerization were unsuccessful. Since they were not soluble in the 
original butyl acrylate/styrene solution, they remained as undesired solids and were not 
encapsulated into the resulting nanoparticles. Therefore, encapsulation studies were not 
feasible. Additionally swelling of the particles so that drug release could be monitored by 
HPLC could not be done, as the swelled polymer was not injectable without resulting in 
column and instrument damage. Experiments involving the breaking of the nanoparticles, 
specifically the polymer core, were also unsuccessful. Around the same time, 
postdoctoral colleagues Raphael Labreure and Renaud Sicard began studies on a novel 
nanoparticle system utilizing poly(vinyl benzoate), PVB, as the polymer core (Figure 
3.1).  
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Figure 3.1 Poly(vinyl benzoate) 
It was postulated that poly(vinyl benzoate) would be biodegradable via hydrolysis, 
yielding poly(vinyl alcohol) and benzoic acid, Figure 3.2, with both of these byproducts 
known to undergo renal excretion from the body.62 
OO
n
Hydrolysis
OH
n
O
OH
n  
Figure 3.2 Degradation pathway of poly(vinyl benzoate) by hydrolysis 
 
Pluronic F-68 was used as the surfactant, and as was seen in the review presented in 
Chapter 1, it is often used as a stabilizer/surfactant in nanoparticle formulations. What 
makes this surfactant so alluring to nanoparticle chemists is its ability to encourage 
intracellular nanoparticle uptake. It has also been shown to increase the circulation time 
of nanoparticles via its enhanced stabilizing properties, in vivo.63  
 
As our laboratory had previously had difficulties incorporating drugs into the 
polyacrylate nanoparticles due to solubility issues, a different method to synthesize these 
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particles was required, with nanoprecipitation chosen as the ideal method.64 When 
utilizing nanoprecipitation, the drug and preformed polymer are dissolved in a readily 
removable organic solvent (miscible with water) that is then added to an aqueous solution 
of the surfactant at a known rate while stirring at vortexing speed. The organic solvent is 
then removed via exposure to the atmosphere, yielding an aqueous suspension of drug 
loaded nanoparticles (Figure 3.3). In 2010, we published this initial work on PVB 
nanoparticles as a potential molecular delivery system.65  
 
 
Figure (3.3) Nanoprecipitation 
 
3.1.1 Synthesis of PVB Nanoparticles 
Using the nanoprecipitation method described earlier, poly(vinyl benzoate) was dissolved 
in acetone (0.5% w/v) and was then added to an aqueous solution containing 0.5% (w/v) 
Pluronic F-68. In our prior publication 5,6-carboxyfluorescein (20) and coumarin-6 (21) 
115 
 
(Figure 3.4) were incorporated into the PVB nanoparticles as fluorescent probes, which 
comprised 1% of the solid content used in the formulation. In these examples, the 
fluorophores were pre-mixed with the poly(vinyl benzoate) prior to nanoprecipitation. 
 
OO OH
COOH
HOOC
N
SO
O
N
20 21  
Figure 3.4 5(6)-carboxyfluorescein (20) and coumarin-6 (21) 
 
3.1.2 Physical Characteristics of PVB Nanoparticles 
Several formulations were used to create the PVB nanoparticles, including surfactant-free 
particles and those incorporating each of the two fluorophores. The samples prepared 
with Pluronic F-68 as a surfactant were between 206 and 256 nm  in diameter, whereas 
the surfactant-free nanoparticles had an average size of 489 nm (Table 3.1). Scanning 
electron microscopy images were also taken of the nanoparticles to further confirm the 
size range, along with the determination of spherical smooth surfaces. 
 
Table 3.1 Average sizes of PVB nanoparticles 
Type of Nanoparticle Average Mean Diameter 
(nm) 
Polydispersity Index 
PVB with Pluronic F-68 
PVB (No surfactant) 
Coumarin-6 
5(6)-Carboxyfluorescein 
256.6 + 7.9 
489.3 + 6.7 
222.8 + 3.1 
206.2 + 2.7 
0.192 + 0.016 
0.381 + 0.010 
0.099 + 0.042 
0.078 + 0.007 
          All data shown as the mean +S.D. All experiments were performed in triplicate. 
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Figure 3.5 SEM images of each nanoparticle formulation. PVB NPs (top left), PVB NPs 
without surfactant (top right), coumarin-6 (bottom left) and 5(6)-carboxyfluorescein 
(bottom right).1 
 
While the above data suggests that the synthesis of these nanoparticles is relatively 
consistent with regards to size, zeta potential is an important characteristic to determine 
whether or not these are stable as emulsions. It is understood within the community that 
nanoparticles with zeta potentials larger than +30 mV are stable as suspensions.66 These 
charges were also studied for all 4 of the nanoparticles synthesized. The empty PVB 
nanoparticles had a zeta potential of -29.2 mV. While this borders the conventional norm 
                                                            
1 Reprinted from Journal of Controlled Release, 148 (2), Raphaël Labruère, Renaud Sicard, Ryan Cormier, 
Edward Turos, Leigh West, Poly(vinyl benzoate) nanoparticles for molecular delivery: Studies on their 
preparation and in vitro properties, 234-40 Copyright (2010), with permission from Elsevier 
117 
 
of stability, the introduction of the two fluorophores greatly increased the stability. 
Coumarin-6 loaded particles were found to have a zeta potential of -56.6 mV and the 
5(6)-carboxyfluorescein loaded particles exhibited a potential of -43.6 mV. The 
nanoparticles without surfactant were much less stable, with a zeta potential around -10 
mV. These results are shown in Table 3.2. 
 
Table 3.2 Zeta potentials for PVB nanoparticles 
Nanoparticles Zeta Potential 
(mV) 
PVB with Pluronic F-68 
PVB (No surfactant) 
Coumarin-6 
5(6)-Carboxyfluorescein 
-29.2 + 1.9 
-10.1 + 0.4 
-56.6 + 0.5 
-43.6 + 0.8 
All data shown as the mean +S.D. All experiments were performed in triplicate 
 
3.1.3 Molecular Loading and In Vitro Molecular Release Studies 
The loading and release of molecules from nanoparticles remains to be one of the most 
important characteristics to be studied for these systems. In order to accomplish this, the 
nanoparticles containing coumarin-6 (21) and 5(6)-carboxyfluorescein (20) were 
destroyed via solvation in dichloromethane and then subjected to HPLC in order to 
determine the concentrations of the compounds (Table 3.3). Coumarin-6 has an 
experimental logP of 5.43, whereas 5(6)-carboxyfluorescein’s logP is -3.45.67 As would 
be expected, the highly lipophilic coumarin-6 was encapsulated incredibly well, with an 
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encapsulation effiency of 78% while the hydrophilic 5(6)-carboxyfluorescein was 
encapsulated at negligible levels.  
Table 3.3 Encapsulation of fluorophores in PVB nanoparticles 
Fluorophore Initial Amount 
(mg) 
Drug Contents 
(% w/w) 
Loading Efficiency 
(% w/w) 
Coumarin-6a 
5(6)-Carboxyfluoresceina 
2 
2 
1.56 + 0.2 
0.005 + 0.0002 
78 + 3.1 
0.25 + 0.08 
All results shown as mean + S.D. a. 100 mg of poly(vinyl benzoate), 100 mg Pluronic 
F68, 20 ml of acetone, and 40 ml of water were used in this formulation. 
 
The coumarin-6 loaded nanoparticles were allowed to stir in PBS buffer for several days 
at 37 °C in order to determine the amount of probe released over time. At particular time 
intervals the media was subjected to HPLC. The nanoparticles were found to exhibit a 
burst release of about 10%, which we postulated corresponds to the amount of probe that 
is adsorbed onto the surface, rather than encapsulated. With 90% of the incorporated drug 
being encapsulated within the nanoparticle, it was interesting to find that only 5% of the 
probe after the initial burst was released over the next several days.  
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Figure 3.6 Coumarin-6 release in PBS buffer at 37 °C from PVB nanoparticles.2  
 
3.1.4 Studies on the Biodegradation Properties of PVB Nanoparticles In Vitro 
It was thought that the PVB polymer would undergo hydrolysis in the body via any of the 
many esterases that exist, and in order to test this hypothesis, the nanoparticles were 
incubated with pig liver esterase in PBS. Both the empty PVB nanoparticles with 
surfactant and surfactant free empty PVB nanoparticles were evaluated (Figure 3.6) by 
determining the amount of benzoic acid released into the media at many differing time 
intervals. The surfactant free nanoparticles exhibited mild degradation, approximately 
18% of benzoic acid detected after 32 days; however, the particles with surfactant 
                                                            
2 Reprinted from Journal of Controlled Release, 148 (2), Raphaël Labruère, Renaud Sicard, Ryan Cormier, 
Edward Turos, Leigh West, Poly(vinyl benzoate) nanoparticles for molecular delivery: Studies on their 
preparation and in vitro properties, 234-40 Copyright (2010), with permission from Elsevier 
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released only 2% of benzoic acid, suggesting a very high protective characteristic of 
Pluronic F-68.  
 
 
Figure 3.7 Poly(vinyl benzoate) degradation as determined via benzoic acid release in 
the presence of pig liver esterase3 
 
3.1.5 Nanoparticle Stability in Rat Blood Serum 
In order for this system to be a viable molecular delivery system, the nanoparticles should 
be able to protect the encapsulated molecule as it makes its way through the blood 
stream, thus the stability of the PVB nanoparticles in blood serum was evaluated. The 
nanoparticles were incubated in rat blood serum for 8 days at 37 °C, after which, SEM 
                                                            
3 Reprinted from Journal of Controlled Release, 148 (2), Raphaël Labruère, Renaud Sicard, Ryan Cormier, 
Edward Turos, Leigh West, Poly(vinyl benzoate) nanoparticles for molecular delivery: Studies on their 
preparation and in vitro properties, 234-40 Copyright (2010), with permission from Elsevier 
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images were taken (Figure 3.8). The nanoparticles are clearly shown to maintain their 
original size and shape, and are not involved in intensive aggregation, providing evidence 
that intravenous injection may be an effective delivery of these particles into a body. 
 
 
Figure 3.8 SEM image of PVB nanoparticles post incubation in blood serum4 
 
3.2. In Vitro Cytotoxicity  
After the departure of Dr. Labreure and Dr. Sicard, several experiments remained to 
further characterize the PVB nanoparticles as molecular delivery systems, most 
                                                            
4 Reprinted from Journal of Controlled Release, 148 (2), Raphaël Labruère, Renaud Sicard, Ryan Cormier, 
Edward Turos, Leigh West, Poly(vinyl benzoate) nanoparticles for molecular delivery: Studies on their 
preparation and in vitro properties, 234-40 Copyright (2010), with permission from Elsevier 
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importantly the evaluation of the cytotoxicity of the PVB nanoparticles. Both human 
epithelial cells and primary bovine aortic endothelial cells were used in this experiment, 
performed in Dr. West’s laboratory. The PVB nanoparticles were found to have 
incredibly high IC50 values against the epithelial cells, above 1000 µg/mL. They fared 
almost as well against the primary bovine aortic endothelial cells, with an IC50 above 500 
µg/mL. Both IC50 values provide convincing evidence that at normal concentrations the 
PVB nanoparticles are not toxic, at least in vitro.  
 
3.3 Use of N-Acyl Ciprofloxacins to Determine the Effects of Varying Lipophilicity 
on Drug Loading and Drug Release 
With the synthesis and initial studies of the PVB nanoparticles done, it became apparent 
that this nanoparticle system could in fact incorporate the N-acyl ciprofloxacins. The 
addition of the acyl groups on the ciprofloxacin skeleton enhanced solubility in organic 
media, which lent itself nicely to the nanoprecipitation method of creating the 
nanoparticles. While the ability to incorporate ciprofloxacin or ciprofloxacin derivatives 
into the nanoparticles was originally desired for antibiotic delivery and activity, it also 
provided an interesting opportunity to evaluate how varying lipophilicity would affect the 
molecular loading and the release of those molecules in vitro.  
 
3.3.1 Synthesis of N-Acyl Ciprofloxacin Loaded Nanoparticles 
Briefly, 100 mg of poly(vinyl benzoate) and 1 mg of N-acyl ciprofloxacin was dissolved 
in 20 ml of acetone and was then added to 40 ml of an aqueous solution containing 100 
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mg of Pluronic F-68. 15 N-acyl ciprofloxacins were incorporated into the nanoparticles, 
comprising 0.5% of the total solid content used in the formulation (Figures 3.9 and 3.10).  
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Figure 3.9 Linear N-acyl ciprofloxacins incorporated into PVB nanoparticles 
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Figure 3.10 Branched N-acyl ciprofloxacins incorporated into PVB nanoparticles 
 
3.3.2 Physical Characteristics of N-Acyl Ciprofloxacin Loaded Nanoparticles 
Average mean diameters of the N-acyl ciprofloxacin loaded nanoparticles were 
determined via dynamic light scattering after sonication to assist in removing 
aggregation. Sizes remained relatively constant, ranging between 230 and 330 nm (Table 
3.4 and Figure 3.11).  
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Table 3.4 Sizes of N-acyl ciprofloxacin loaded nanoparticles 
Nanoparticle N-Acyl Ciprofloxacin Particle Size 
(nm) 
Polydispersity Index 
NP1 
NP2 
NP3 
NP5 
NP6 
NP7 
NP8 
NP9 
NP10 
NP11 
NP12 
NP14 
NP15 
NP16 
NP18 
Control 
1 
2 
3 
5 
6 
7 
8 
9 
10 
11 
12 
14 
15 
16 
18 
None 
253.4 + 7.853 
281.3 + 15.35 
234.0 + 1.762 
240.7 + 5.916 
228.8 + 5.807 
269.6 + 10.01 
253.2 + 4.766 
272.8 + 15.40 
251.2 + 9.079 
277.5 + 9.246 
295.9 + 11.17 
307.4 + 4.869 
330.2 + 0.264 
314.9 + 8.688 
291.9 + 3.580 
218.8 + 2.718 
0.168 + 0.037 
0.237 + 0.009 
0.186 + 0.008 
0.125 + 0.029 
0.151 + 0.013 
0.158 + 0.023 
0.134 + 0.028 
0.243 + 0.07 
0.135 + 0.076 
0.187 + 0.075 
0.175 + 0.053 
0.246 + 0.011 
0.211 + 0.012 
0.218 + 0.012 
0.204 + 0.009 
0.086 + 0.010 
All data shown as mean + S.D. All experiments were performed in triplicate. 
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Figure 3.11 Graphical representation of N-acyl ciprofloxacin loaded nanoparticle sizes 
 
The nanoparticles’ zeta potential values were also evaluated in order to confirm stability. 
As can be seen in Table 3.5, nearly all of the nanoparticles pass the -30 mV threshold, 
and those that did not were relatively close, suggesting that the N-acyl ciprofloxacin 
loaded nanoparticles are stable as suspensions.  
  
 
 
 
 
 
0
50
100
150
200
250
300
350
Av
er
ag
e 
M
ea
n 
Di
am
et
er
 (n
m
) 
NP # 
127 
 
Table 3.5 Zeta Potentials of N-acyl ciprofloxacin loaded nanoparticles 
Nanoparticle N-Acyl Ciprofloxacin Zeta Potential 
(mV) 
NP1 
NP2 
NP3 
NP4 
NP5 
NP6 
NP7 
NP8 
NP9 
NP10 
NP11 
NP12 
NP13 
NP14 
NP15 
Control 
1 
2 
3 
5 
6 
7 
8 
9 
10 
11 
12 
14 
15 
16 
18 
None 
-28.8 + 4.7 
-28.9 + 2.53 
-41.3 + 3.54 
-35.9 + 4.87 
-31.2 + 4.85 
-34.5 + 6.23 
-37.7 + 4.18 
-35.0 + 5.61 
-40.0 + 0.50 
-46.8 + 1.89 
-36.2 + 0.67 
-39.5 + 2.28 
-34.9 + 1.04 
-27.8 + 0.82 
-33.0 + 3.07 
-29.4 + 1.29 
All data shown as Mean + S.D. 
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3.3.3 N-Acyl Ciprofloxacin Drug Loading 
Previously, two fluorescent probes were encapsulated into the PVB nanoparticles, 5(6)-
carboxyfluorescein and coumarin-6, however, they only represented two extremes of 
lipophilicity, with Log P of -3.45 and 5.43, respectively. While it was shown that 
extremely hydrophilic molecules would not be encapsulated in the nanoparticles, it was 
not shown how varying degrees of lipophilicity would affect the drug loading and the 
release of those drugs. One would hypothesize that a highly lipophilic drug would lead to 
a stronger interaction between the drug and the environment within the nanoparticle 
diminishing the capability of the drug to be released. Table 3.6 shows the drug loading of 
each N-acyl ciprofloxacin within the respective nanoparticles. The nanoparticles prepared 
with the least lipophilic drugs, NP1 and NP2, had no drug loading whatsoever, whereas 
the nanoparticle prepared with the most lipophilic drug, NP8, showed a drug loading of 
3.64 μg/mg NP. While the entire library of N-acyl ciprofloxacins tested varied with 
calculated logP, it can be separated into two different types, those with linear acyl groups 
and ones with various branching. The entire library is represented in Figures 3.12 and 
3.13, while the types are shown in Figures 3.14 and 3.15. While examining the entire 
library it can be seen that the more lipophilic the drug, the higher the encapsulation. 
However, the linear N-acyl derivatives give a much better trend than the branched ones, 
indicating that various types of branching on the acyl chain also has an effect on drug 
loading aside from the hydrophobic aspect. 
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Table 3.6 N-acyl ciprofloxacin loading into PVB nanoparticles 
Nanoparticle N-Acyl Ciprofloxacin Drug Loading 
(µg Drug / mg NP) 
NP1 
NP2 
NP3 
NP5 
NP6 
NP7 
NP8 
NP9 
NP10 
NP11 
NP12 
NP14 
NP15 
NP16 
NP18 
1 
2 
3 
5 
6 
7 
8 
9 
10 
11 
12 
14 
15 
16 
18 
0 
0 
0.38 + 0.0019 
2.13 + 0.1950 
2.36 + 0.2567 
1.68 + 0.2320 
2.82 + 0.3918 
3.64 + 0.0115 
1.02 + 0.0699 
0.23 + 0.0170 
0.69 + 0.0777 
1.15 + 0.0139 
1.68 + 0.0256 
2.20 + 0.2151 
0.64 + 0.0579 
Values are shown as Mean + S.E. All experiments were performed in triplicate. 
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Figure 3.12 Degree of loading of N-acyl ciprofloxacins into PVB nanoparticles 
organized by increasing calculated logP values 
0
0.5
1
1.5
2
2.5
3
3.5
4
1 2 10 3 9 15 11 12 4 5 14 13 6 7 8
Dr
ug
 L
oa
di
ng
 
µg
 D
ru
g 
/ 
m
g 
N
P 
NP 
131 
 
 
Figure 3.13 N-acyl ciprofloxacin loading into PVB versus logP values 
 
Figure 3.14 Degree of loading of linear N-acyl ciprofloxacin into PVB nanoparticles 
organized by increasing calculated logP (left) and plotted versus logP (right). 
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Figure 3.15 Degree of loading of branched N-acyl ciprofloxacin into PVB nanoparticles 
organized by increasing calculated logP (left) and plotted versus logP (right). 
 
3.3.4  In Vitro Release of N-Acyl Ciprofloxacins From PVB Nanoparticles 
The drug release studies would be expected to yield an inverse trend to that of the drug 
loading study, with the more lipophilic drugs having a lower propensity for release than 
those of higher hydrophilicity, which is what was observed. Figures 3.16 and 3.17 show 
drug release at 24 hours and at 96 hours for those nanoparticles, versus drug loading. It 
can be seen in Figure 3.16 that the nanoparticles containing the more hydrophilic drugs 
released a large percentage of incorporated drug within the first 24 hours, suggesting that 
the majority of those N-acyl ciprofloxacins were adsorbed onto the surface, resulting in 
an initial burst release. The more lipophilic N-acyl ciprofloxacins at 24 hours released 
minimal amounts of drug, usually less than 20%, and by 96 hours had only shown a slight 
increase in initial release, providing evidence that most of the drug is encapsulated within 
the nanoparticle. 
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Figure 3.16 N-acyl ciprofloxacin release from PVB nanoparticles, organized by 
increasing calculated logP at both 24 and 96 hours 
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Figure 3.17 N-acyl ciprofloxacin release from PVB nanoparticles versus logP at both 24 
and 96 hours 
 
3.3.5 Antimicrobial Activity 
None of the tested N-acyl ciprofloxacin loaded nanoparticles exhibited any activity 
against E. coli and MRSA in vitro. We attribute this to the large protective characteristic 
of the surfactant coated nanoparticles. While this makes it difficult to assess the 
effectiveness of PVB nanoparticles as molecular/drug delivery vehicles, it is important to 
understand that the environment in vivo is harsher than that of in vitro.  
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3.4 Conclusions and Future Directions 
This chapter discusses the synthesis and characterization of the PVB nanoparticles in an 
effort to contribute to the determination of the efficacy of PVB nanoparticles as 
molecular delivery vehicles. The nanoparticles were created via nanoprecipitation of 
poly(vinyl benzoate) and resulted in particle sizes between 200 and 330 nm. They were 
also found to be stable in suspensions with most zeta potential values being larger than -
30 mV. The particles were found to be nontoxic toward human epithelial and primary 
bovine aortal endothelial cells and stable in rat blood serum. Use of the N-acyl 
ciprofloxacins’ varying degrees of lipophilicity demonstrated a clear trend with regards to 
encapsulation and release. Relatively hydrophilic compounds were not incorporated into 
the nanoparticles. Weakly lipophilic compounds were adsorbed onto the surface of the 
particles in small amounts, however, this also resulted in a large percentage of burst 
release during the in vitro release studies. Compounds with modest to high calculated 
logPs were encapsulated in larger quantities rather than adsorbed onto the surface, 
indicated by the small amount of burst release within the first 24 hours in the PBS media. 
The lack of antimicrobial activity in vitro suggests that the nanoparticles maintain a 
strong hold on the encapsulated molecules and that harsher conditions would be 
necessary for their release, such as those present in vivo. 
 
While significant progress has been made on the PVB nanoparticle system, more work 
needs to be done to truly evaluate these particles as potential molecular delivery agents. 
As we now have a better understanding of molecular loading, highly bioactive 
compounds should be incorporated into these nanoparticles for an increased chance at in 
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vitro antimicrobial activity. Studies that exploit the difference in incorporation of the 
molecules should also be explored. It would be interesting to see if one could incorporate 
a weakly lipophilic drug on the surface primarily, followed by a second more lipophilic 
drug within the particle. Such a system would allow a burst release of one drug, followed 
by a long term delivery of a second. Perhaps synthetic modifications could be made so 
that one molecule is derivatized to be adsorbed and another modification allows it to be 
encapsulated, allowing the particles to demonstrate both a burst and long term release of 
a drug.  
 
More importantly, and perhaps enlightening, would be the evaluation of this system in 
vivo. Particularly, biodistribution studies need to be done in order to see how these 
particles move throughout the body. The use of radiolabeling and fluorescent probes 
would indicate if and where these particles accumulate, potentially resulting in more 
targeted therapeutic endeavors. Determining the uptake of these nanoparticles is also 
needed to distinguish which types of organs/tissues are more susceptible to these 
particles.  
 
The several studies that have been presented, along with many others, are vital in the 
implementation of these systems as potential molecular delivery agents.  
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CHAPTER 4 
 
CONCLUSIONS 
 
 
Primarily, our research interest for this work involved the evaluation of lipophilicity on 
the molecular loading and release from polymeric nanoparticles developed in our 
laboratory via synthetic modifications to known antibiotics.  
 
The thesis begins with a review of the field of nanoparticle-based delivery for antibiotics, 
as outlined and discussed in Chapter 1. From this, it is possible to find pockets of 
untapped, under-explored areas suitable for research that is of current interest to our 
laboratory. 
 
Being that much of the research in our laboratory over the past ten years has been in 
antibiotics discovery and chemical synthesis, this project was initiated as a follow-up to 
previous dissertation research on both antibiotic agents for controlling drug-resistant 
bacteria, and their incorporation into organic nanoparticles. One of these areas centers on 
ways to better utilize ciprofloxacin, a commercial antibiotic, for drug-resistant Staph 
infections common to hospitals and community-acquired infections. In Chapter 2, 
structurally new N-acyl ciprofloxacins were evaluated for antibacterial activity against a 
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narrow selection of both Gram-positive and Gram-negative bacteria. Although no general 
structure-activity relationship for these compounds was observed, increases in 
lipophilicity were accompanied by decreased antimicrobial activity. The compounds also 
showed promising in vitro activity against Bartonella hensalae, an intracellular microbe. 
The ciprofloxacin derivatives were shown to utilize the same mode of action as other 
fluoroquinolones via inhibition of DNA gyrase. Our studies also indicated that they were 
less prone to induce MRSA to develop resistance. Collectively, these results suggest that 
N-acyl ciprofloxacins may be potential antibiotics for clinical applications. A United 
States patent (#8,143,398) was issued to the University of South Florida on March 27, 
2012, with the title of “Activity of New N-Acylated Ciprofloxacin Derivatives Against 
Facultative Intracellular Bacteria”. In addition, these results were published in Bioorganic 
and Medicinal Chemistry Letters, entitled “Studies on the Antimicrobial Properties of N-
Acylated Ciprofloxacin Derivatives”, and presented at several research conferences. 
 
A second aspect of this project, described in Chapter 3, involved the incorporation of 
ciprofloxacin derivatives in organic nanoparticles. Our laboratory had previously 
published work on the incorporation of beta-lactam antibiotics in polyacrylate 
nanoparticles, prepared by emulsion polymerization. These nanoparticles are formed in 
an aqueous emulsion and have potent antibacterial properties. Ciprofloxacin and its N-
acrylated derivative were used in an attempt to incorporate the antibiotic either covalently 
or via encapsulation into the matrix of the poly(butyl acrylate-styrene) nanoparticles 
during emulsion polymerization. However, these efforts were thwarted by the poor 
solubility of the compounds in the acrylate mixture, which led to the development of N-
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acyl ciprofloxacin derivatives. Unfortunately, these analogues also had poor solubility, 
and could not be implemented in the formation of the desired polyacrylate nanoparticles. 
Therefore, a different type of nanoparticle and preparation procedure was needed.  
At the same time the ciprofloxacin studies were being done, two postdoctorals in our 
laboratory, Dr. Renaud Sicard and Dr. Raphael Labreure began some initial work on 
poly(vinyl benzoate) (PVB) nanoparticles. They found that coumarin-6 and 5(6)-
carboxyfluoroscein, which were used as fluorescent probes, had different encapsulation 
properties, suggesting that the PVB nanoparticles may have utility for lipophilic agents 
(including perhaps antibiotics). However, a true understanding of what molecules could 
be loaded into these particles and their molecular release was needed. Utilizing the N-
acyl ciprofloxacins, PVB nanoparticles were prepared by nanoprecipitation, yielding 
particles as stable suspensions whose sizes remained relatively constant (250 to 300 nm). 
Drug loading studies demonstrated that the more lipophilic N-acyl ciprofloxacin 
analogues were encapsulated at higher amounts than the less lipophilic derivatives. Drug 
release profiles indicated that the N-acyl ciprofloxacins having a low predicted logP (low 
lipophilicity) underwent significant release rapidly, suggesting that the compounds were 
most likely adsorbed onto the surface of the nanoparticle rather than becoming 
encapsulated within the polymeric matrix. The more highly lipophilic analogues were 
shown to undergo a slower drug release over the first 24 hours, which may indicate that a 
higher percentage of the compound is contained within the nanoparticle rather than on the 
outer surface. 
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With these studies, we now have a better understanding of the effect of lipophilicity of 
the drug molecule on molecular loading into and release from PVB nanoparticles. This 
data will be useful in the future to design nanoparticles and antibiotic agents in a more 
desired/designed fashion.  
 
With such a vast array of synthetic options available to organic chemists, there are many 
opportunities for future studies, including structural modifications to the surface of the 
nanoparticles to introduce new properties or physical characteristics. Small molecules can 
be synthesized to better fit the requirements necessary for optimal use of the poly(vinyl 
benzoate) nanoparticles. 
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CHAPTER 5 
 
MATERIALS AND METHODS 
 
 
5.1 Synthetic Procedures for N-Acyl Ciprofloxacins 
 
5.1.1 Materials 
All chemicals used were purchased from Sigma Aldrich and used without purification. 
Thin layer chromatography was done using Silica Gel 60 F254, which was purchased from 
EMD Chemicals. NMR spectroscopy was performed using deuterated chloroform on an 
Inova 400 MHz instrument. 
 
5.1.2 General Methods for the Synthesis of N-Acyl Ciprofloxacins. 
Method A: Ciprofloxacin (500 mg, 1.5 mmol) and triethylamine (300 μl, 2 mmol) were 
stirred in 20 mL of methylene chloride at 0 °C for 15 min. The desired acyl chloride (2.25 
mmol) was added dropwise. The suspension was allowed to stir at room temperature until 
a clear solution was observed. To this solution, hexane was added drop wise until a white 
precipitate formed. The precipitate was then filtered off and dried. If further purification 
was needed, the desired compound was isolated via flash chromatography on silica gel 
using 20% methanol in dichloromethane as the eluent. 
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Method B: Ciprofloxacin (500 mg, 1.5 mmol) and triethylamine (300 uL, 2 mmol) were 
stirred in 20 mL of methylene chloride at 0 °C for 15 min. The desired acid anhydride (3 
mmol) was added dropwise. The suspension was allowed to stir at room temperature until 
a clear solution was observed. To this solution, hexane was added drop wise until a white 
precipitate formed. The precipitate was then filtered off and dried. If further purification 
was needed, the desired compound was isolated via flash chromatography using 20% 
methanol in dichloromethane as the eluent. 
 
O
N
F
N
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HO
O1  
1: Obtained 460 mg (81%) as an off-white solid. Melting Point: >260 °C. 1H NMR (400 
MHz, CDCl3) δ ppm 8.70 (s, 1 H) 7.96 (d, J=12.8 Hz, 1 H) 7.34 (d, J=6.6 Hz, 1 H) 3.77 
(m, 4 H) 3.53 (br. s., 1 H) 3.31 (m, 4 H) 2.14 (s, 3 H) 1.38 (d, J=5.4 Hz, 2 H) 1.18 (br. s., 
2 H); 13C NMR (101 MHz, CDCl3) δ ppm 177.0 (d, J=3.0 Hz), 169.1, 166.8, 153.6 (d, 
J=250.0 Hz), 147.5, 145.4 (d, J=10.7 Hz), 139.0, 120.2 (d, J=7.6 Hz), 112.5 (d, J=23.0 
Hz), 108.1, 50.1, 49.4, 46.0, 41.0, 35.3, 21.3, 8.2 
 
O
N
F
N
N
O
HO
O2  
143 
 
2: Obtained 530 mg (91%) as an off-white solid. Melting Point: >260 °C. 1H NMR (400 
MHz, CDCl3) δ ppm 8.69 (s, 1 H) 7.95 (d, J=12.8 Hz, 1 H) 7.33 (d, J=6.6 Hz, 1 H) 3.77 
(m, 4 H) 3.53 (br. s., 1 H) 3.31 (m, 4 H) 2.39 (q, J=7.4 Hz, 2 H) 1.37 (d, J=5.0 Hz, 2 H) 
1.17 (m, 5 H); 13C NMR (101 MHz, CDCl3) δ ppm 176.9 (d, J=3.1 Hz), 172.4, 166.7, 
153.6 (d, J=251.6 Hz), 147.4, 145.4 (d, J=10.9 Hz), 138.9, 112.4 (d, J=23.2Hz), 108.1, 
105.0 (d, J=3 Hz), 50.1, 49.3, 45.1, 41.1, 35.3, 26.4, 9.3, 8.2  
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3: Obtained 589 mg (97%) as an off-white solid. Melting Point: >260 °C. 1H NMR (400 
MHz, CDCl3) δ ppm 8.73 (s, 1 H) 8.00 (d, J=12.9 Hz, 1 H) 7.34 (d, J=7.0 Hz, 1 H) 3.79 
(m, 4 H) 3.53 (m, 1 H) 3.30 (m, 4 H) 2.35 (m, 2 H) 1.69 (m, 2 H) 1.38 (d, J=6.6 Hz, 2 H) 
1.18 (d, J=2.7 Hz, 2 H) 0.98 (t, J=7.4 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 
177.0, 171.6, 166.8, 154.8 (d, J=251.5 Hz), 147.5, 145.4 (d, J=10.7 Hz), 138.97, 120.3 (d, 
J=9.1 Hz) 112.6 (d, J=24.5 Hz), 108.2, 105.0 (d, J=3.0 Hz), 50.3, 49.4, 41.0, 35.2, 35.1, 
18.6, 13.9, 8.2 
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4: Obtained 423 mg (68%) as an off-white solid. Melting Point: >260 °C 1H NMR (400 
MHz, CDCl3) δ ppm 8.56 (br. s., 1 H) 7.79 (d, J=12.0 Hz, 1 H) 7.29 (d, J=7.4 Hz, 1 H) 
3.76 (m, 4 H) 3.54 (m, 1 H) 3.30 (m, 4 H) 2.34 (t, J=8.0 Hz, 2 H) 1.59 (quin, J=7.5 Hz, 2 
H) 1.34 (m, 4 H) 1.16 (m, 2 H) 0.89 (t, J=7.2 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ 
ppm 176.7, 171.8, 166.5, 153.5 (d, J=250.1 Hz), 147.3, 145.3 (d, J=11.0 Hz), 138.9, 
119.6, 112.0 (d, J=23.4 Hz), 107.7, 105.0 (d, J=4.1 Hz), 50.1, 49.3, 45.3, 41.0, 35.3, 32.9, 
27.3, 22.5, 13.8, 8.1 
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5: Obtained 531 mg (83%) as an off-white solid. Melting Point: 204-206 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 0.80 (t, J=6.3 Hz, 3 H) 1.10 (m, 2 H) 1.28 (m, 6 H) 1.55 (br. s., 
2 H) 2.29 (t, J=7.4 Hz, 2 H) 3.23 (m, 4 H) 3.52 (br. s., 1 H) 3.72 (m, 4 H) 7.24 (br. s., 1 
H) 7.66 (d, J=12.9 Hz, 1 H) 8.46 (br. s., 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 176.5, 
171.8, 166.5, 153.3 (d, J=251.6 Hz), 147.2, 145.3 (d, J=7.6 Hz), 138.8, 119.4 (d, J=9.9 
Hz), 111.7 (d, J=20.7 Hz), 107.5, 105.0 (d, J=3.2 Hz), 49.9, 49.3, 45.2, 41.0, 35.3, 33.1, 
24.8, 22.3, 13.8, 8.1 
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6: Obtained 560 mg (84%) as an off-white solid. Melting Point: 162-164 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.66 (s, 1 H) 7.92 (d, J=12.9 Hz, 1 H) 7.32 (d, J=7.0 Hz, 1 H) 
3.77 (m, 4 H) 3.53 (tt, J=7.0, 3.7 Hz, 1 H) 3.31 (m, 4 H) 2.35 (t, J=8.0 Hz, 2 H) 1.63 
(quin, J=7.5 Hz, 2 H) 1.33 (m, 8 H) 1.17 (m, 2 H) 0.86 (t, J=8.0 Hz, 3 H); 13C NMR (101 
MHz, CDCl3) δ ppm 176.9, 171.8, 166.7, 153.5 (d, J=252.6 Hz), 147.4, 145.4 (d, J=9.3 
Hz), 138.9, 120.0, 112.3 (d, J=24.9 Hz), 108.0, 105.0 (d, J=3.4 Hz), 50.1, 49.3, 45.3, 
41.0, 35.2, 33.2, 31.5, 29.1, 25.2, 22.5, 14.0, 8.2 
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7: Obtained 656 mg (95%) as an off-white solid. Melting Point: 154-156 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.70 (s, 1 H) 7.96 (d, J=12.9 Hz, 1 H) 7.33 (d, J=7.0 Hz, 1 H) 
3.77 (m, 4 H) 3.53 (br. s., 1 H) 3.31 (m, 4 H) 2.36 (t, J=7.8 Hz, 2 H) 1.65 (s, 2 H) 1.32 
(m, 12 H) 0.86 (t, J=7.0 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 177.0, 171.8, 
166.7, 153.6 (d, J=250.3 Hz), 147.4, 145.4 (d, J=10.7 Hz), 138.9, 120.1, 112.5 (d, J=23.0 
Hz), 108.1, 105.0 (d, J=3.4 Hz), 50.2, 49.4, 45.3, 41.0, 35.2, 33.2, 31.6, 29.4, 29.0, 25.2, 
22.5, 14.0, 8.2 
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8: Obtained 693 mg (96%) as an off-white solid. Melting Point: 136-142 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.73 (s, 1 H) 8.00 (d, J=12.9 Hz, 1 H) 7.34 (d, J=7.0 Hz, 1 H) 
3.80 (m, 4 H) 3.52 (m, 1 H) 3.30 (m, 4 H) 2.36 (t, J=7.4 Hz, 2 H) 1.64 (m, 2 H) 1.28 (m, 
14 H) 0.86 (t, J=7.0 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 177.0, 171.8, 166.7, 
153.5 (d, J=248.7 Hz), 147.5, 145.4 (d, J=10.8 Hz), 138.9, 120.3, 112.6 (d, J=21.6 Hz), 
108.2, 105.0 (d, J=2.9 Hz), 50.3, 49.4, 45.3, 41.0, 35.2, 33.2, 31.7, 29.4, 29.3, 29.1, 25.2, 
22.6, 14.0, 8.2 
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9: Obtained 233 mg (32%) as an off-white solid. Melting Point: 130-136 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.63 (s, 1 H) 7.88 (d, J=5.1 Hz, 1 H) 7.31 (d, J=6.6 Hz, 1 H) 
3.76 (m, 4 H) 3.53 (br. s., 1 H) 3.30 (m, 4 H) 2.35 (t, J=7.6 Hz, 2 H) 1.62 (m, 2 H) 1.29 
(m, 16 H) 0.84 (dd, J=7.0, 5.5 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 176.8, 
171.9, 166.7, 153.4 (d, J=251.6 Hz), 147.4, 145.4 (d, J=9.2 Hz), 138.9, 119.9, 112.3 (d, 
J=23.0 Hz), 107.9, 105.1 (d, J=3.1 Hz), 50.2, 49.4, 45.4, 41.1, 35.3, 33.2, 31.8, 29.3, 25.3, 
22.6, 14.1, 8.2  
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10: Obtained 530 mg (85%) as an off-white solid. Melting Point: >260 °C. 1H NMR (400 
MHz, CDCl3) δ ppm  8.70 (s, 1 H) 7.96 (d, J=12.9 Hz, 1 H) 7.33 (d, J=7.0 Hz, 1 H) 3.87 
(m, 4 H) 3.52 (m, 1 H) 3.31 (m, 4 H) 1.38 (m, 2 H) 1.30 (s, 9 H)1.19 (m, 2 H); 13C NMR 
(101 MHz, CDCl3) δ 177.0, 176.6, 166.8, 153.6 (d, J=250.0 Hz), 147.5, 145.4 (d, J=10.7 
Hz), 139.0, 120.1, 112.5 (d, J=24.6 Hz), 108.1, 105.0 (d, J=3.0 Hz), 49.9, 49.8, 44.8, 
38.7, 35.3, 28.4, 8.2 
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11: Obtained 462 mg (68%) as an off-white solid. Melting Point: >260 °C. 1H NMR (400 
MHz, CDCl3) δ ppm 8.7 (s, 1 H) 7.9 (d, J=12.9 Hz, 1 H) 7.3 (d, J=7.0 Hz, 1 H) 3.8 (m, 4 
H) 3.5 (br. s., 1 H) 3.3 (m, 4 H) 2.3 (d, J=7.0 Hz, 2 H) 2.1 (dt, J=13.5, 6.5 Hz, 1 H) 1.4 (d, 
J=6.6 Hz, 2 H) 1.2 (br. s., 2 H) 1.0 (d, J=6.6 Hz, 6 H); 13C NMR (101 MHz, CDCl3) δ 
ppm 177.0, 171.1, 166.7, 153.5 (d, J=250.0 Hz), 147.5, 145.4 (d, J=10.7 Hz), 139.0, 
120.1, 112.5 (d, J=24.6 Hz), 108.1, 105.1 (d, J=3.0 Hz), 50.3, 49.5, 45.6, 42.0, 41.0, 35.3, 
25.7, 22.5, 8.2 
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12: Obtained 343 mg (53%) as an off-white solid. Melting Point: 182-184 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.77 (s, 1 H) 8.05 (d, J=12.5 Hz, 1 H) 7.34 (d, J=7.8 Hz, 1 H) 
3.88 (m, 4 H) 3.51 (m, 1 H) 3.30 (m, 4 H) 1.66 (q, J=8.0 Hz, 2 H) 1.39 (m, 2 H) 1.27 (m, 
6 H) 1.19 (m, 2 H) 0.91 (t, J=7.8 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ 177.1, 175.8, 
166.9, 153.6 (d, J=251.6 Hz), 147.6, 145.4 (d, J=10.7 Hz), 139.0, 138.9, 120.4, 112.7 (d, 
J=23.0 Hz), 108.3, 104.9, 50.0, 49.9, 44.7, 43.0, 35.3, 33.3, 26.5, 9.5, 8.3 
 
O
N
F
N
N
O
HO
O13  
13: Obtained 389 mg (58%) as an off-white solid. Melting Point: 248-254 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.68 (s, 1 H) 7.94 (d, J=12.9 Hz, 1 H) 7.33 (d, J=7.0 Hz, 1 H) 
3.85 (m, 4 H) 3.53 (dd, J=7.0, 3.5 Hz, 1 H) 3.31 (m, 4 H) 2.54 (tt, J=8.2, 5.3 Hz, 1 H) 
1.66 (m, 2 H) 1.50 (m, 2 H) 1.38 (q, J=6.5 Hz, 2 H) 1.18 (m, 2 H) 0.88 (t, J=7.4 Hz, 6 H); 
13C NMR (101 MHz, CDCl3) δ ppm 176.9, 174.6, 166.8, 153.5 (d, J=251.6 Hz), 147.5, 
145.4 (d, J=10.7 Hz), 139.0, 120.1, 112.4 (d, J=24.6 Hz), 108.1, 105.0 (d, J=3.0 Hz), 
50.5, 49.6, 45.4, 44.1, 41.3, 35.3, 25.5, 12.1, 8.2 
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14: Obtained 504 mg (78%) as an off-white solid. Melting Point: 182-184 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.7 (s, 1 H) 8.0 (d, J=13.0 Hz, 1 H) 7.3 (d, J=7.1 Hz, 1 H) 3.8 
(m, 4 H) 3.5 (br. s., 1 H) 3.3 (d, J=16.7 Hz, 4 H) 2.7 (m, 1 H) 1.3 (m, 8 H) 1.1 (d, J=6.8 
Hz, 3 H) 0.9 (t, J=6.8 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ 176.9, 175.4, 166.8, 
153.5 (d, J=253.1 Hz), 147.5, 145.4 (d, J=10.7 Hz), 139.0, 120.0, 112.4 (d, J=23.0 Hz) 
108, 108.0, 105.0 (d, J=3.1 Hz), 50.4, 49.5, 45.3, 41.2, 36.2, 35.1, 20.6, 17.5, 14.1, 8.2 
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15: Obtained 331 mg (48%) as an off-white solid. Melting Point: 178-179 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.54 (s, 1 H) 7.74 (d, J=12.9 Hz, 1 H) 7.27 (d, J=4.7 Hz, 1 H) 
3.79 (m, 4 H) 3.53 (br. s., 1 H) 3.28 (m, 4 H) 2.65 (m, 1 H) 1.59 (m, 2 H) 1.25 (m, 10 H) 
0.83 (t, J=7.2 Hz, 6 H); 13C NMR (101 MHz, CDCl3) δ ppm 176.7, 175.0, 166.7, 153.4 
(d, J=250.1 Hz), 147.3, 145.3 (d, J=10.7 Hz), 138.9, 119.6 (d, J=7.7 Hz), 112.0 (d, J=27.6 
Hz), 107.7, 105.0 (d, J=3.0 Hz), 50.3, 49.5, 45.4, 41.2, 40.4, 35.4, 35.1, 20.8, 14.1, 8.1 
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16: Obtained 646 mg (93%) as an off-white solid. Melting Point: 138-150 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.61 (s, 1 H) 7.84 (d, J=13.3 Hz, 1 H) 7.30 (d, J=7.0 Hz, 1 H) 
3.86 (m, 4 H) 3.53 (br. s., 1 H) 3.30 (m, 4 H) 2.58 (m, 1 H) 1.64 (m, 2 H) 1.34 (m, 10 H) 
0.85 (m, 5 H); 13C NMR (101 MHz, CDCl3) δ ppm 176.8 (d, J=3.1 Hz),174.9, 166.7, 
153.5 (d, J=251.6 Hz), 147.4, 145.3 (d, J=10.7 Hz), 138.9, 119.8 (d, J=7.7 Hz), 112.2 (d, 
J=23.0 Hz), 107.9, 50.4, 49.6, 45.4, 42.5, 41.2, 35.3, 32.3, 29.8, 25.9, 22.8, 14.0, 12.1, 8.2 
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17: Obtained 386 mg (54%) as an off-white solid. Melting Point: 204-206 °C. 1H NMR 
(400 MHz, CDCl3) δ ppm 8.7 (s, 1 H) 7.9 (d, J=12.5 Hz, 1 H) 7.3 (d, J=6.3 Hz, 1 H) 3.8 
(m, 4 H) 3.5 (m, 1 H) 3.3 (m, 4 H) 2.3 (m, 2 H) 2.1 (m, 1 H) 1.4 (d, J=6.3 Hz, 2 H) 1.2 
(m, 4 H) 1.0 (d, J=6.3 Hz, 3 H) 0.9 (m, 9 H); 13C NMR (101 MHz, CDCl3) δ 176.9, 
171.2, 166.7, 153.5 (d, J=251.6 Hz), 147.4, 145.4 (d, J=10.7 Hz), 139.0, 120.0, 112.3 (d, 
J=23.0 Hz), 108.0, 105.0 (d, J=3.0 Hz), 50.8, 50.3, 49.4, 45.5, 42.5, 41.0, 35.3, 31.1, 30.0, 
27.1, 22.9, 8.2 
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18: Obtained 572 mg (87%) as an off-white solid. Melting point: >260 °C. 1H NMR (400 
MHz, CDCl3) δ ppm 8.8 (s, 1 H) 8.0 (d, J=12.5 Hz, 1 H) 7.5 (m, 6 H) 3.9 (m, 4 H) 3.6 
(br. s., 1 H) 3.4 (m, 4 H) 1.4 (d, J=6.6 Hz, 2 H) 1.2 (br. s., 2 H); 13C NMR (101 MHz, 
CDCl3) δ 176.0, 153.9 (d, J=253.1 Hz), 148.1, 145.9 (d, J=9.2 Hz), 139.4, 132.9, 131.1, 
128.9, 127.1, 119.1, 116.2, 113.4, 112.4 (d, J=24.5 Hz), 106.9, 105.3 (d, J=3.1 Hz), 50.1, 
49.0, 47.8, 42.5, 36.1, 8.2 
 
5.2 Antimicrobial Testing for N-Acyl Ciprofloxacins 
 
5.2.1 Bacterial Growth Conditions 
E. coli, S. aureus, E. faecalis, B. anthracis and S. cerevisae testing was done in Dr. 
Lindsey Shaw’s laboratory (Department of Cell Biology). As previously published, E. 
coli was grown in Luria-Bertani medium, E. faecalis, B. anthracis, and S. aureus were 
grown in tryptic soy broth, and S. cerevisiae was grown in yeast extract peptone 
dextrose.53 Bartonella strains were cultured using chocolate agar prepared from heart 
infusion agar base supplemented with 5% bovine hemoglobin at 37 °C in 5% CO2, done 
in Dr. Anderson’s laboratory (College of Medicine). 
 
5.2.2 Disk Diffusion Assays 
Disk diffusion assays for E. coli, S. aureus, E. faecalis, and S. cerevisae obtained from 
glycerol stocks were streaked on to the growth media and incubated. An inoculate liquid 
media was obtained via the removal of a single colony from the growth media, and this 
was incubated overnight. E. coli, S. aureus, and E. faecalis cultures were diluted 1:1,000 
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into 5 ml of molten overlay agar prior to the implementation of inoculate growth plates. 
After drying, three sterile filter disks per plate were added. 50 ug of drug per disk were 
added and the bacterial plates were allowed to incubate for 24 hours. The diameter of the 
inhibitory area was measured in mm. Bartonella disk diffusion assays were performed as 
previously published.57 20 µl of a 1 mg/ml solution of drug was spotted onto the center of 
a 6 mm paper disk on aluminum foil. These were sealed in a bag along with a desiccant at 
4 °C. Growth (after 4 days) was resuspended in 1 ml of sterile Heart Infusion Broth and 
the turbidity was adjusted to a McFarland 2.0. This suspension was spread over a 
chocolate agar plate and was allowed to dry. The disks were placed in the center of the 
paltes, inverted, and incubated for one week. Zones of inhibition were measured in the 
same way as the other bacteria described. 
 
5.2.3 Minimum Inhibitory Concentration Assays 
Minimum inhibitory concentrations for E. coli, S. aureus, E. faecalis, and S. cerevisae 
were determined in Dr. Shaw’s laboratory as previously reported.53 The bacteria was 
diluted 1:1,000 in tryptic soy broth and 200 µl of this stock was pipetted into sterile 96-
well plates. DMSO solutions of the desired drug were added in decreasing concentrations 
(by half) to the wells, at volumes less or equal to 5 µl. The plates were incubated at 37 °C 
and the MIC values were determined via visual inspection. Testing of Bartonella strains 
(performed in Dr. Anderson’s laboratory) was done via agar dilution method. Drug 
solutions at concentrations of 10.0, 1.0 and 0.1 µg/ml were tested on chocolate agar 
plates and testing was completed using the same procedure utilized for disk diffusion 
assays described in 4.2.1.  
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5.2.4 Spontaneous Mutation Frequencies 
Testing was done in Dr. Lindsey Shaw’s laboratory (Department of Cell Biology). TSB 
agar (TSA) was prepared containing N-acyl ciprofloxacin derivatives 2a, 2i or 2m at 
concentrations equivalent to 1x, 1.5x, 2.0x and 2.5x the experimentally-determined MIC 
for MSSA. For 2b, TSA plates were prepared at a concentration equivalent to 2.5x MIC 
for MSSA. Overnight broth cultures of MSSA were prepared as described previously8, 
with 1 ml aliquots extracted, and cells harvested by centrifugation. Supernatants were 
removed, and pellets resuspended in 100 μl of fresh TSB. These preparations were then 
used to inoculate the N-acyl ciprofloxacin-containing agar, and spread using sterile glass 
beads. The colony forming units (cfu) per ml of the inoculating culture was determined 
via serial dilution into TSA containing no antibiotic compound. Spontaneous mutation 
frequencies were calculated by dividing the number of colonies obtained by the total 
bacterial load inoculated. 
 
5.2.5 Sequence Analysis of Quinolone Binding Domains 
DNA was extracted from spontaneously resistant MSSA mutants using a DNeasy kit 
(Qiagen), according to the manufacturer’s instructions. Samples were subject to DNA 
sequencing reactions (MWG) using primers specific for the Quinolone Resistance-
Determining Regions (QRDR) of the gyrAB and grlAB genes of S. aureus, as described 
previously by Horii et al.68 
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5.2.6 Intracellular Activity Assay 
The HMEC-1 human microvascular endothelial cell line was maintained in MCDB131 
medium supplemented with 10% FBS, 5% L-glutamine, 10 ng/ml EGF, and 1 μg/ml 
hydrocortisone. The HMEC-1 cells were infected with the Houston-1 strain of B. 
henselae at a multiplicity of infection of 100 for 4 hours as previously described. After 
infection, the cells were washed 2x with PBS, then treated with gentamicin (200 μg/ml) 
for 1 hour to kill extracellular adherent bacteria. Infected cells were washed as before and 
media with the test antibiotics were added at concentrations of 0.1 μg/ml and 1.0 μg/ml. 
After addition of test antibiotics, infected cells were incubated for 96 hours. Following 
incubation, the antibiotics were removed, the infected cells were washed as before, and 
lysed with 0.1% saponin. Lysates were plated on chocolate agar and incubated for 7 days. 
After incubation, the CFU/ml were counted to determine the number of viable bacteria. 
 
5.2.7 DNA Gyrase Assay 
The activity of select compounds against DNA gyrase was tested using relaxed circular 
pUC19 DNA in the presence of E. coli DNA gyrase and antibiotics at concentrations of 
1.0 μg/ml, 5.0 μg/ml, 10 μg/ml, and 25 μg/ml. Samples were incubated at 37 °C for 1 
hour then analyzed by gel electrophoresis to quantify the amount of relaxed and 
supercoiled DNA, as previously described.69 
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5.3 Preparation and Characterization of Poly(vinyl benzoate) Nanoparticles 
 
5.3.1 Materials 
Poly(vinyl benzoate) (average molecular weight 20,000-70,000) was obtained from 
Monomer-Polymer and Dajac Labs, Inc. (Feasturville, PA). Acetone, methanol, 
dichloromethane, phosphate buffered saline (PBS), ciprofloxacin, Pluronic F68, Tween 
80, trifluoroacetic acid (TFA), acetonitrile (HPLC grade) and water (HPLC grade) were 
purchased from Sigma-Aldrich (St. Louis, MO).  
 
5.3.2 Preparation of Nanoparticles 
As previously described, typically 100 mg of poly(vinyl benzoate) was dissolved in 20 
mL of acetone and then added to a 40 ml aqueous solution containing 100 mg of 
Pluronic-F68 at a rate of approximately 1 ml/min, while maintaining stirring speed such 
that a vortex occurred.65 After which, the resulting mixture was allowed to stand at room 
temperature for 12 hours without cappin as to allow the acetone to evaporate, leaving a 
suspension of nanoparticles. This suspension was subjected to centrifugation at 15,000 
rpm for 10 minutes, after which the supernatant was removed and fresh water added. This 
was sonicated to allow resuspension and then centrifuged twice more. After the final 
centrifugation was complete, the supernantant was removed and small amounts of water 
were added to create a concentrated suspension. The suspension was frozen and 
lyophilized to yield 48.6 mg of pure powdered nanoparticles. For nanoparticles 
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containing N-acyl ciprofloxacins, 1 mg of drug was dissolved in the acetone/poly(vinyl 
benzoate) solution before introduction to the aqueous surfactant solution. 
5.3.3 Determination of Particle Size and Zeta Potential 
The emulsions were sonicated to ensure that there were no aggregation products and then 
submitted to dynamic light scattering (DLS) measurements to determine particle size 
using a Malvern Nano ZS instrument. Experiments were performed in triplicate. The zeta 
potentials for the drug loaded nanoparticles were determined via micro-electrophoresis on 
the same instrument. 
 
5.3.4 Determination of Drug Loading 
1.0 mg of lyophilized N-acyl ciprofloxacin loaded nanoparticle was dissolved in 1.0 ml 
of dichloromethane and allowed to stir for 5 hours to permit nanoparticle swelling. The 
dichloromethane was evaporated and 1.0 ml of acetonitrile was added. This was 
sonicated and filtered through a .2 micron syringe filter. High performance liquid 
chromatography (HPLC) was performed on an Agilent 1100 series with a reverse phase 
Kinetix column (C18, 0.46 x 5 cm). Samples were eluted using a gradient from 90:10 
water:acetonitrile to 100% of acetonitrile in 12.5 minutes at a flow rate of 1.3 mL/min. 
The detection was performed using an Agilent UV-visible detector at 284 nm. The 
concentration of the requisite N-acyl ciprofloxacin was determined via comparison to a 
known concentration using a standardized calibration curve. 
 
5.3.5 In vitro Drug Release Study 
157 
 
Each N-acyl ciprofloxacin loaded nanoparticle sample was tested for in vitro release of 
the corresponding drug. A suspension of 2 mg of lyophilized drug loaded nanoparticles in 
1 ml phosphate buffered saline (PBS) containing Tween 80 (0.1% v:v) was stirred at 150 
rpm for 96 hours at 37 °C. At 2, 10, 24 and 96 hours, the suspension was centrifuged. The 
1 mL of supernatant was removed. 1 ml of fresh media was added to continue the 
experiment. The previously removed supernantant was subjected to HPLC analysis. The 
concentration of the drug in the supernatant was compared to known concentrations via 
standardized calibration curves as previously described in method 2.5. Drug release was 
determined via the following formula: 
Drug Release % = concentration of drug released (per mg of NP) / original concentration 
of drug (per mg of NP) 
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SPECTRA, DLS, AND ZETA POTENTIAL DATA 
 
 
RC5-17H.esp
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
or
m
al
iz
ed
 In
te
ns
ity
2.081.872.903.890.904.000.910.950.95
N
O
OH
O
F
N
N
O
CH3
 
Figure (A1): 1H NMR (400 MHz, CDCl3) of Compound 1 
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Figure (A2): 13C NMR (400 MHz, CDCl3) of Compound 1 
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Figure (A3): 1H NMR (400 MHz, CDCl3) of Compound 2 
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Figure (A4): 13C NMR (400 MHz, CDCl3) of Compound 2 
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Figure (A5): 1H NMR (400 MHz, CDCl3) of Compound 3 
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Figure (A6): 13C NMR (400 MHz, CDCl3) of Compound 3: 
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Figure (A7): 1H NMR (400 MHz, CDCl3) of Compound 4 
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Figure (A8): 13C NMR (400 MHz, CDCl3) of Compound 4 
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Figure (A9): 1H NMR (400 MHz, CDCl3) of Compound 5 
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Figure (A10): 13C NMR (400 MHz, CDCl3) of Compound 5 
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Figure (A11): 1H NMR (400 MHz, CDCl3) of Compound 6 
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Figure (A12): 13C NMR (400 MHz, CDCl3) of Compound 6 
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Figure (A13): 1H NMR (400 MHz, CDCl3) of Compound 7 
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Figure (A14): 13C NMR (400 MHz, CDCl3) of Compound 7 
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Figure (A15): 1H NMR (400 MHz, CDCl3) of Compound 8 
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Figure (A16): 13C NMR (400 MHz, CDCl3) of Compound 8 
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Figure (A17): 1H NMR (400 MHz, CDCl3) of Compound 9 
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Figure (A18): 13C NMR (400 MHz, CDCl3) of Compound 9 
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Figure (A19): 1H NMR (400 MHz, CDCl3) of Compound 10 
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Figure (A20): 13C NMR (400 MHz, CDCl3) of Compound 10 
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Figure (A21): 1H NMR (400 MHz, CDCl3) of Compound 11 
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Figure (A22): 13C NMR (400 MHz, CDCl3) of Compound 11 
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Figure (A23): 1H NMR (400 MHz, CDCl3) of Compound 12 
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Figure (A24): 13C NMR (400 MHz, CDCl3) of Compound 12 
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Figure (A25): 1H NMR (400 MHz, CDCl3) of Compound 13 
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Figure (A26): 13C NMR (400 MHz, CDCl3) of Compound 13 
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Figure (A27): 1H NMR (400 MHz, CDCl3) of Compound 14 
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Figure (A28): 13C NMR (400 MHz, CDCl3) of Compound 14 
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Figure (A29): 1H NMR (400 MHz, CDCl3) of Compound 15 
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Figure (A30): 13C NMR (400 MHz, CDCl3) of Compound 15 
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Figure (A31): 1H NMR (400 MHz, CDCl3) of Compound 16 
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Figure (A32): 13C NMR (400 MHz, CDCl3) of Compound 16 
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Figure (A33): 1H NMR (400 MHz, CDCl3) of Compound 17 
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Figure (A34): 13C NMR (400 MHz, CDCl3) of Compound 17 
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Figure (A35): 1H NMR (400 MHz, CDCl3) of Compound 18 
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Figure (A36): 13C NMR (400 MHz, CDCl3) of Compound 18 
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Figure (A37): Dynamic Light Scattering Results for NP1 
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Figure (A38): Dynamic Light Scattering Results for NP2 
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Figure (A39): Dynamic Light Scattering Results for NP3 
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Figure (A40): Dynamic Light Scattering Results for NP5 
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Figure (A41): Dynamic Light Scattering Results for NP6 
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Figure (A42): Dynamic Light Scattering Results for NP7 
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Figure (A43): Dynamic Light Scattering Results for NP8 
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Figure (A44): Dynamic Light Scattering Results for NP9 
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Figure (A45): Dynamic Light Scattering Results for NP10 
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Figure (A46): Dynamic Light Scattering Results for NP11 
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Figure (A47): Dynamic Light Scattering Results for NP12 
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Figure (A48): Dynamic Light Scattering Results for NP14 
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Figure (A49): Dynamic Light Scattering Results for NP15 
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Figure (A50): Dynamic Light Scattering Results for NP16 
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Figure (A51): Dynamic Light Scattering Results for NP18 
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Figure (A52): Zeta Potential for NP1 
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Figure (A53): Zeta Potential for NP2 
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Figure (A54): Zeta Potential for NP3 
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Figure (A55): Zeta Potential for NP5 
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Figure (A56): Zeta Potential for NP6 
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Figure (A57): Zeta Potential for NP7 
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Figure (A58): Zeta Potential for NP8 
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Figure (A59): Zeta Potential for NP9 
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Figure (A60): Zeta Potential for NP10 
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Figure (A61): Zeta Potential for NP11 
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Figure (A62): Zeta Potential for NP12 
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Figure (A63): Zeta Potential for NP14 
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Figure (A64): Zeta Potential for NP15 
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Figure (A65): Zeta Potential for NP16 
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Figure (A66): Zeta Potential for NP18 
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Table (A1): HPLC retention times for N-acyl ciprofloxacins 
 
Ciprofloxacin Time (minutes) 
3 4.87 
5 5.96 
6 6.52 
7 7.03 
8 7.57 
9 8.05 
10 5.46 
11 5.33 
12 5.90 
14 5.87 
15 5.78 
16 6.75 
18 5.34 
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Figure (A67): HPLC Chromatogram for Drug Loading of NP3 
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Figure (A68): HPLC Chromatogram for Drug Loading of NP5 
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Figure (A69): HPLC Chromatogram for Drug Loading of NP6 
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Figure (A70): HPLC Chromatogram for Drug Loading of NP7 
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Figure (A71): HPLC Chromatogram for Drug Loading of NP8 
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Figure (A72): HPLC Chromatogram for Drug Loading of NP9 
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Figure (A73): HPLC Chromatogram for Drug Loading of NP10 
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Figure (A74): HPLC Chromatogram for Drug Loading of NP11 
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Figure (A75): HPLC Chromatogram for Drug Loading of NP12 
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Figure (A76): HPLC Chromatogram for Drug Loading of NP14 
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Figure (A77): HPLC Chromatogram for Drug Loading of NP15 
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Figure (A78): HPLC Chromatogram for Drug Loading of NP16 
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Figure (A79): HPLC Chromatogram for Drug Loading of NP18 
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Figure (A80): HPLC Chromatogram of Drug Release at 10 Hours for NP3 
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Figure (A81): HPLC Chromatogram of Drug Release at 24 Hours for NP3 
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Figure (A82): HPLC Chromatogram of Drug Release at 96 Hours for NP3 
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Figure (A83): HPLC Chromatogram of Drug Release at 10 Hours for NP5 
 
 
 
 
 
 
 
 
 
 
233 
 
0 6 12
0
1
2
m
AU
Time (minutes)
 
Figure (A84): HPLC Chromatogram of Drug Release at 24 Hours for NP5 
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Figure (A85): HPLC Chromatogram of Drug Release at 96 Hours for NP5 
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Figure (A86): HPLC Chromatogram of Drug Release at 10 Hours for NP6 
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Figure (A87): HPLC Chromatogram of Drug Release at 24 Hours for NP6 
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Figure (A88): HPLC Chromatogram of Drug Release at 96 Hours for NP6 
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Figure (A89): HPLC Chromatogram of Drug Release at 10 Hours for NP7 
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Figure (A90): HPLC Chromatogram of Drug Release at 24 Hours for NP7 
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Figure (A91): HPLC Chromatogram of Drug Release at 96 Hours for NP7 
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Figure (A92): HPLC Chromatogram of Drug Release at 10 Hours for NP8 
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Figure (A93): HPLC Chromatogram of Drug Release at 24 Hours for NP8 
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Figure (A94): HPLC Chromatogram of Drug Release at 96 Hours for NP8 
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Figure (A95): HPLC Chromatogram of Drug Release at 2 Hours for NP9 
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Figure (A96): HPLC Chromatogram of Drug Release at 10 Hours for NP9 
 
 
 
 
 
 
 
 
 
 
246 
 
0 6 12
0.0
0.8
1.6
m
AU
Time (minutes)
 
Figure (A97): HPLC Chromatogram of Drug Release at 24 Hours for NP9 
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Figure (A98): HPLC Chromatogram of Drug Release at 96 Hours for NP9 
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Figure (A99): HPLC Chromatogram of Drug Release at 10 Hours for NP10 
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Figure (A100): HPLC Chromatogram of Drug Release at 24 Hours for NP10 
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Figure (A101): HPLC Chromatogram of Drug Release at 96 Hours for NP10 
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Figure (A102): HPLC Chromatogram of Drug Release at 2 Hours for NP11 
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Figure (A103): HPLC Chromatogram of Drug Release at 10 Hours for NP11 
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Figure (A104): HPLC Chromatogram of Drug Release at 24 Hours for NP11 
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Figure (A105): HPLC Chromatogram of Drug Release at 96 Hours for NP11 
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Figure (A106): HPLC Chromatogram of Drug Release at 2 Hours for NP12 
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Figure (A107): HPLC Chromatogram of Drug Release at 10 Hours for NP12 
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Figure (A108): HPLC Chromatogram of Drug Release at 24 Hours for NP12 
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Figure (A109): HPLC Chromatogram of Drug Release at 96 Hours for NP12 
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Figure (A110): HPLC Chromatogram of Drug Release at 2 Hours for NP14 
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Figure (A111): HPLC Chromatogram of Drug Release at 10 Hours for NP14 
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Figure (A112): HPLC Chromatogram of Drug Release at 24 Hours for NP14 
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Figure (A113): HPLC Chromatogram of Drug Release at 96 Hours for NP14 
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Figure (A114): HPLC Chromatogram of Drug Release at 2 Hours for NP15 
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Figure (A115): HPLC Chromatogram of Drug Release at 10 Hours for NP15 
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Figure (A116): HPLC Chromatogram of Drug Release at 24 Hours for NP15 
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Figure (A117): HPLC Chromatogram of Drug Release at 96 Hours for NP15 
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Figure (A118): HPLC Chromatogram of Drug Release at 2 Hours for NP16 
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Figure (A119): HPLC Chromatogram of Drug Release at 10 Hours for NP16 
 
 
 
 
 
 
 
 
 
 
269 
 
0 6 12
0
1
2
3
m
AU
Time (minutes)
 
Figure (A120): HPLC Chromatogram of Drug Release at 24 Hours for NP16 
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Figure (A121): HPLC Chromatogram of Drug Release at 96 Hours for NP16 
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Figure (A122): HPLC Chromatogram of Drug Release at 2 Hours for NP18 
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Figure (A123): HPLC Chromatogram of Drug Release at 10 Hours for NP18 
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Figure (A124): HPLC Chromatogram of Drug Release at 24 Hours for NP18 
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Figure (A125): HPLC Chromatogram of Drug Release at 96 Hours for NP18 
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APPENDIX 2 
 
 
Figures 3.5, 3.6, 3.7 and 3.8 have been previously published and used with permission. 
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